University of South Carolina

Scholar Commons
Theses and Dissertations
2018

Kv7 Channels Of The Urinary Bladder Smooth Muscle: Functional
Roles And Therapeutic Potential
Aaron Provence
University of South Carolina

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Provence, A.(2018). Kv7 Channels Of The Urinary Bladder Smooth Muscle: Functional Roles And
Therapeutic Potential. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/4659

This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please
contact digres@mailbox.sc.edu.

KV7 CHANNELS OF THE URINARY BLADDER SMOOTH MUSCLE: FUNCTIONAL
ROLES AND THERAPEUTIC POTENTIAL
by
Aaron Provence
Bachelor of Science
University of South Carolina, 2012

Submitted in Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy in
Pharmaceutical Sciences
College of Pharmacy
University of South Carolina
2018
Accepted by:
Lorne J. Hofseth, Major Professor
Jun Zhu, Chair, Examining Committee
Mark Hamann, Committee Member
Jill Turner, Committee Member
Kenneth B. Walsh, Committee Member
Cheryl L. Addy, Vice Provost and Dean of the Graduate School

© Copyright by Aaron Provence, 2018
All Rights Reserved

ii

DEDICATION
To my mother and father.

iii

ACKNOWLEDGEMENTS
I thank the members of my PhD Advisory Committee: Drs. Lorne J. Hofseth, Jun Zhu, Jill
Turner, Mark Hamann, and Kenneth B. Walsh. I would like to thank Dr. Kiril L. Hristov
for his mentorship and training during the course of my PhD. I also thank Drs. Shankar P.
Parajuli, Vitor S. Fernandes, Wenkuan Xin, Gary P. Schools, Damiano Angoli, and Biao
Chen for their support and teamwork. I further thank Dr. Eric S. Rovner for his mentorship
and the Department of Urology at the Medical University of South Carolina (MUSC).
Specifically, I thank the MUSC Urology staff surgeons: Drs. Thomas Keane, Harry Clarke,
Stephen Savage, Ross Rames, Sandip Prasad, and Jonathan Picard, as well as the MUSC
Urology Residents: Ryan Levey, Austin Younger, Mark Currin, Nima Baradaran,
Olugbemisola McCoy, Alyssa Greiman, Sarah Starosta, Bryce Wyatt and Tracy Tipton for
their help with human tissue collection. I thank my Graduate Program Director, Dr. Lorne
Hofseth and Department Chair Dr. Kim Creek for their unwavering support and guidance
throughout my PhD.

iv

ABSTRACT
Overactive bladder (OAB) is a pervasive and debilitating condition for which
effective therapeutic modalities are lacking. As potential novel pharmacological targets for
lower urinary tract dysfunction, our recent studies have demonstrated voltage-gated KV7
channels (KV7.1-KV7.5) to be functionally expressed in detrusor smooth muscle (DSM) of
the urinary bladder. Nonetheless, the specific roles of individual K V7 channel subtypes
remains poorly understood. Using Western blot, immunocytochemistry, isometric DSM
tension

recordings,

ratiometric

fluorescence

Ca2+

imaging,

and

patch-clamp

electrophysiology, we demonstrated expression and key physiologic roles for the
KV7.2/KV7.3 channels in guinea pig DSM using the novel and selective K V7.2/KV7.3
channel opener N-(2-Chloro-5-pyrimidinyl)-3,4-difluorobenzamide (ICA-069673). We
further sought to pharmacologically target KV7.4- and KV7.5-containing channels, which
evidence suggests are the prominent subtypes expressed in smooth muscle, to determine
their involvement in regulating DSM excitation-contraction coupling. The novel
KV7.4/KV7.5

channel

activator

N-(2,4,6-Trimethylphenyl)-bicyclo[2.2.1]heptane-2-

carboxamide (ML213) was shown to enhance KV7 channel currents in isolated DSM cells,
hyperpolarize the DSM cell membrane potential, and attenuate the contractile activity of
DSM isolated strips via a Ca2+-dependent mechanism. ML213 exhibited significantly
greater potency for inhibition of DSM contractility in comparison to K V7.2/KV7.3 channel
opener

ICA-069673.

Using

in

situ

proximity

ligation

assay

(PLA), it was further revealed KV7.4 and KV7.5 channel α-subunits co-localize to form

v

heteromeric KV7.4/KV7.5 channel complexes in DSM isolated cells. These studies suggest
KV7.4/KV7.5 channels are functionally expressed in guinea pig DSM, where they critically
regulate DSM excitability and contractility.
Finally, to ascertain the translational implications of our aforementioned findings
from experimental animals, we examined KV7 channel expression and function in human
DSM. KV7 channel activators and inhibitors were shown to attenuate and potentiate,
respectively, human DSM excitability and contractility in normal and OAB samples.
Noteworthy, using in situ PLA, we confirmed the molecular interaction between K V7.4 and
KV7.5 channel α-subunits, suggesting heteromeric KV7.4/KV7.5 channel subtype
expression at the cellular level in human DSM cells. These findings are consistent with our
findings

in

guinea

pig

DSM and provide strong support to suggest K V7.4/KV7.5 channels are among the key
subtypes regulating human DSM function.
In

conclusion,

our

combined

studies

reveal

novel insights into the expression, subunit composition, and physiological roles of K V7
channel in DSM, providing critical information for directing future research efforts
concerning the utility of KV7 channels as therapeutic targets for OAB.
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CHAPTER 1
INTRODUCTION
Urinary Bladder Structure, Function, and Regulation
The urinary bladder facilitates two major functions: the storage and voiding of
urine. Under physiological conditions, parasympathetic nerves release ACh and ATP to
activate muscarinic ACh receptors (mAChRs) and purinergic receptors, respectively, to
trigger bladder contraction and micturition (i.e. urine voiding)[1-3]. Within the walls of the
urinary bladder detrusor smooth muscle (DSM), the main muscular component of the
bladder, facilitates bladder contraction in response to mAChR activation. In human DSM,
ACh-induced activation of mAChRs constitutes the primary mechanism initiating bladder
contraction in urine voiding [1]. In addition to these nerve-mediated mechanisms, human
DSM also exhibits spontaneous action potentials, intrinsic activity of the DSM cells which
underlies the spontaneous phasic contractility of the bladder.
DSM contractility is mainly dependent upon an increase in global intracellular Ca2+
concentrations ([Ca2+]i) as the rise in [Ca2+]i leads to the activation of myosin-light chain
kinase pathways which underlies smooth muscle contractility (23, 44). As exemplified by
Figure 1.2, ACh-induced activation of mAChRs can increases global intracellular Ca2+
concentrations via phospholipase C-mediated activation of sarcoplasmic reticulum IP3
receptors, which results in the release of Ca2+ from internal stores. Release of Ca2+ from
the sarcoplasmic reticulum results in a dramatic increase in the local Ca2+ concentration,
which can result in the activation of adjacent cation channels at the cell membrane.
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Critically involved in the regulation of bladder contractility, K + channels function to
regulate Ca2+ entry through L-type voltage-gated Ca2+ (Cav) channels, and thus intracellular
Ca2+ levels, by virtue of their influence upon the cell membrane potential[4]. While the
etiology and pathophysiology of overactive bladder (OAB) is not fully known, it has been
directly linked to DSM dysfunction. As such, the pivotal role of the K + channels in
controlling DSM cell membrane excitability has generated interest in their potential
therapeutic utility for various forms of DSM dysfunction and OAB.

1

Figure 1.1 Schematic drawing of the bladder.
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Reprinted from Andersson & Arner, 2004[1] with permission.
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2

Figure 1.2. Signal pathways (1–4) involved in activation of detrusor contraction via
muscarinic M3 receptors. ACh, acetylcholine; PLC, phospholipase C; DAG,
diacylglycerol; PKC, protein kinase C; MLC, myosin light chain; IP 3, inositol
trisphosphate; SR, sarcoplasmic reticulum; CIC, calcium-induced calcium release. There
seem to be differences between species in the contribution of the different pathways in
contractile activation. In human detrusor, Ca2+ influx (3) is of major importance.

2

Reprinted from Andersson & Arner, 2004[1] with permission.

3

Overactive bladder
Overactive bladder (OAB) is currently among the most prevalent chronic health
conditions in the United States with significant economic and health-related implications
(47). As a syndrome, OAB is characterized by the lower urinary tract symptoms (LUTS)
experienced by the individual, which includes urinary urgency, frequency, with or without
urge urinary incontinence and nocturia (22). Despite the negative physical, social, and
economic impact of OAB, evidence demonstrates this condition to have a detrimental
impact upon individual’s mental health and quality of life by interfering with their sleep,
work, and social interactions (33, 34). Affecting ~16.5% of the population, the increasing
prevalence of OAB is expected to continue and by the year 2018, it will impact an estimated
20.1% of the population at a cost of $82.6 billion (13, 27). However, these estimations
underscore the widespread impact of OAB because as little as 25% of individuals affected
actually pursue medical care (16).
The primary treatment for OAB involves antimuscarinics (i.e. anticholinergics);
however, these agents are not tissue- or organ-specific in their mechanism of action and
thus give rise to bothersome side-effects including blurred vision, dry-mouth, and
tachycardia (16, 19). This is evidenced by the current patient discontinuation rates of 8090% within the first year of treatment (18) with one report indicating the average time for
patient discontinuation to be 31 days (15). More recently, a β3-adrenoceptor agonist known
as mirabegron was approved by the FDA to treat OAB; however, its long-term efficacy is
inconclusive (19). Likewise, intradetrusor botulinum toxin type A (OnabotulinumtoxinA)
injections approved by the FDA in 2013 have shown to provide some effective
symptomatic relief, yet this method of treatment is both invasive, requires IV sedation, and
may call for recurrent injections to maintain clinical effectiveness (16). Therefore, the
4

considerable negative effects OAB has upon individual health, both physically and
psychologically, dictates an urgent need for improved pharmacological therapeutics.
The storage and periodical release of urine describes the two major functions of the
urinary bladder (5), a process facilitated by the contraction and relaxation of urinary
bladder smooth muscle (UBSM) (39). UBSM contractility is mainly dependent upon
increased intracellular Ca2+ concentrations ([Ca2+]i) as the rise in [Ca2+]i leads to the
activation of myosin-light chain kinase pathways which underlies smooth muscle
contractility (23, 44). Therefore, if the goal of OAB therapeutics is to promote UBSM
relaxation, it is essential therefore to consider the key mechanisms controlling Ca 2+ influx
within human UBSM cells. This precisely defines the fundamental role of UBSM K +
channels, which by promoting cell membrane hyperpolarization, precludes Ca2+-influx
through L-type (long-lasting) voltage-gated Ca2+ (Cav) channels to promote membrane
hyperpolarization and thus UBSM relaxation (6, 9).
Voltage-gated KV7 Channels
Among all K+ channels, the voltage-gated KCNQ family has been shown to serve
functional roles in rat, guinea pig (3,12 25) and human UBSM (26); however, among the
40 genes encoding these channels, a subfamily of five channels encoded by KCNQ genes
(KCNQ1-KCNQ5) have sparked great interest as potential pharmacological targets based
on increasing evidence suggesting their involvement in a number of pathophysiological
conditions including epilepsy, hypertension, chronic pain, and cardiac dysfunction (11, 20,
35, 40). The KCNQ (or Kv7) channel family (KCNQ1-KCNQ5) attains vast heterogeneity
as their five α subunits form distinct homo- or hetero-tetrameric complexes (see Figure
1.3a) (42, 50). Further, KCNQ channels associate with KCNE-encoded β-regulatory
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subunits (KCNE1-KCNE5), which may alter KCNQ channel biophysical properties
including subcellular localization, pharmacology, and selectivity (1, 14, 30, 42, 48).
The knowledge of KCNQ channel expression and function primarily arose from studies in
the heart and brain, however physiological roles for KCNQ channels in other vascular and
non-vascular tissues systems is now becoming more apparent (28, 29, 31, 32, 36, 43, 51).
The important physiological roles KCNQ channels serve in various tissues has coincided
with an increasing number of KCNQ channel pharmacological modulators, which has
further heightened our understanding of these channels along with revealing some key
distinctions between KCNQ channels and other smooth muscle K + channels (30).
Previously, the therapeutic utility of K+ channel pharmacological activators, specifically
KATP channels activators, were unsuccessful due to concerns regarding drug
selectivity[1]. However, this changed in 2011 with the FDA approval of the antiepileptic
drug retigabine, which exerts its therapeutic effects by targeting KCNQ2-5 channels (21).
This has led to retigabine being widely utilized throughout various tissues and animal
models in order to elucidate KCNQ channel function in health and disease (30).
Noteworthy and pertinent to this work, KCNQ channel functional roles, including
in studies from our laboratory (2), have recently been identified within UBSM tissues of
the guinea pig (2, 4), pig (46); and rat, where retigabine was shown to have pronounced
effects in reducing UBSM contractility (41). This may elude to the increased micturition
volume and voiding intervals observed in rats subjected to acute retigabine exposure in
vivo (41, 45, 46). More relevant, clinical evidence has proven retigabine to be associated
with the increased occurrence of urinary retention (9). This indicates a potential role for
KCNQ channel activity in regulating bladder function and therefore targeting these
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channels may potentially provide beneficial relief for patients with OAB. While retigabine
is a potent activator of KCNQ2-5 channels, the selectivity towards KCNQ2/3 channels is
significantly greater than that of KCNQ4/5 as evidenced by experimentally determined
EC50 values of 0.6 µM for KCNQ2/3 and 5.2-6.4 µM for KCNQ4/5 (21). KCNQ4 and
KCNQ5 channel expression is predominate in smooth muscle (44) with KCNQ2/3
channels important for neuronal function. This could be very significant as this may
suggest the potential pharmacological efficacy of future selective KCNQ4/5 channel
activators as effective treatments for OAB, while KCN2/3 selective modulators may prove
better for the treatment of neurological conditions. Therefore, this may abolish the large
number of adverse effects associated with current OAB treatments and thus the beneficial
implications of this research is incredibly relevant to public health, clinical medicine, and
most importantly, quality of life.

7

3

Figure 1.3 Structure and function of K+ channels. (a) Planar membrane topologies of
single potassium channel subunits for KV , BK Ca , and K ir channels, respectively. The
pore-forming loop and the voltage sensor in transmembrane unit 4 are indicated. (b)
Representative current traces recorded in human pulmonary arterial smooth muscle cells
indicating diversity in the Kv currents; from left to right, (1) rapidly activating and slowly
inactivating I K(V), (2) rapidly activating and noninactivating I K(V) , (3) slowly activating
and noninactivating I K(V) , and (4) rapidly activating and rapidly inactivating I K(V)K.

3

Reprinted from Firth et al, 2011[5] with permission.
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4

Figure 1.4 Efferent pathways of the lower urinary tract
a | Innervation of the female lower urinary tract. Sympathetic fibres (shown in blue)
originate in the T11–L2 segments in the spinal cord and run through the inferior mesenteric
ganglia (inferior mesenteric plexus, IMP) and the hypogastric nerve (HGN) or through the
paravertebral chain to enter the pelvic nerves at the base of the bladder and the urethra.
Parasympathetic preganglionic fibres (shown in green) arise from the S2–S4 spinal
segments and travel in sacral roots and pelvic nerves (PEL) to ganglia in the pelvic plexus
(PP) and in the bladder wall. This is where the postganglionic nerves that supply
parasympathetic innervation to the bladder arise. Somatic motor nerves (shown in yellow)
that supply the striated muscles of the external urethral sphincter arise from S2–S4 motor
neurons and pass through the pudendal nerves. b | Efferent pathways and neurotransmitter
mechanisms that regulate the lower urinary tract. Parasympathetic postganglionic axons in
the pelvic nerve release acetylcholine (ACh), which produces a bladder contraction by
stimulating M3 muscarinic receptors in the bladder smooth muscle. Sympathetic
postganglionic neurons release noradrenaline (NA), which activates β3 adrenergic
receptors to relax bladder smooth muscle and activates α1 adrenergic receptors to contract
urethral smooth muscle. Somatic axons in the pudendal nerve also release ACh, which
produces a contraction of the external sphincter striated muscle by activating nicotinic
cholinergic receptors. Parasympathetic postganglionic nerves also release ATP, which
excites bladder smooth muscle, and nitric oxide, which relaxes urethral smooth muscle (not
shown). L1, first lumbar root; S1, first sacral root; SHP, superior hypogastric plexus; SN,
sciatic nerve; T9, ninth thoracic root. Part amodified, with permission, from REF. 144 © (1996)
W. B. Saunders Company.
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Reprinted from Fowler et al., 2010[6] with permission.
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CHAPTER 2
EXPERIMENTAL APPROACH
Rationale and Central Hypothesis
The important physiological role KV7 channels serve in smooth muscle tissues, which
evidence shows to be subtype- and tissue-specific, suggests these channels may provide a
novel platform for future OAB pharmacological treatments. The achievement of this will
require an improved understanding of KV7 channel expression, subunit composition, and
function in DSM excitability and contractility at both the single cell and whole-tissue level.
The central hypothesis of these studies is that KV7 channels are critical regulators of
human UBSM excitation-contraction coupling and thus KV7 channels provide a novel
target for the pharmacological treatment of OAB.

10

5

Figure 1.5. Neural circuits that control continence and micturition
a | Urine storage reflexes. During the storage of urine, distention of the bladder produces
low-level vesical afferent firing. This in turn stimulates the sympathetic outflow in the
hypogastric nerve to the bladder outlet (the bladder base and the urethra) and the pudendal
outflow to the external urethral sphincter. These responses occur by spinal reflex pathways
and represent guarding reflexes, which promote continence. Sympathetic firing also
inhibits contraction of the detrusor muscle and modulates neurotransmission in bladder
ganglia. A region in the rostral pons (the pontine storage centre) might increase striated
urethral sphincter activity. b | Voiding reflexes. During the elimination of urine, intense
bladder-afferent firing in the pelvic nerve activates spinobulbospinal reflex pathways
(shown in blue) that pass through the pontine micturition centre. This stimulates the
parasympathetic outflow to the bladder and to the urethral smooth muscle (shown in green)
and inhibits the sympathetic and pudendal outflow to the urethral outlet (shown in red).
Ascending afferent input from the spinal cord might pass through relay neurons in the
periaqueductal grey (PAG) before reaching the pontine micturition centre. Note that these
diagrams do not address the generation of conscious bladder sensations, nor the
mechanisms that underlie the switch from storage to voiding, both of which presumably
involve cerebral circuits above the PAG. R represents receptors on afferent nerve terminals.

5

Reprinted from Fowler et al., 2010[6] with permission
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CHAPTER 3
6

THE NOVEL KV7.2/KV7.3 CHANNEL OPENER ICA-069673 REVEALS SUBTYPESPECIFIC FUNCTIONAL ROLES IN GUINEA PIG DETRUSOR SMOOTH MUSCLE
EXCITABILITY AND CONTRACTILITY

ABSTRACT
The physiological roles of voltage-gated KV7 channel subtypes (KV7.1-KV7.5) in
detrusor smooth muscle (DSM) are poorly understood. Here, we sought to elucidate the
functional roles of KV7.2/KV7.3 channels in guinea pig DSM excitability and contractility
using the novel KV7.2/KV7.3 channel activator N-(2-chloro-pyrimidin-5-yl)-3,4-difluorobenzamide (ICA-069673). We employed a multi-level experimental approach using
Western blot, immunocytochemistry with confocal microscopy, isometric DSM tension
recordings, fluorescence Ca2+ imaging, and perforated whole cell patch-clamp
electrophysiology. Western blot experiments revealed the protein expression of K V7.2 and
KV7.3 channel subunits in DSM tissue. In isolated DSM cells, immunocytochemistry with
confocal microscopy further confirmed protein expression for K V7.2 and KV7.3 channel
subunits where they localize within the vicinity of the cell membrane. ICA-069673
inhibited spontaneous phasic, pharmacologically-induced, and nerve-evoked contractions
in DSM isolated strips in a concentration-dependent manner. The inhibitory effects of ICA069673 on DSM spontaneous phasic and tonic contractions were abolished in the presence

6

Provence, A., J. Malysz, and G.V. Petkov, The Novel KV7.2/KV7.3 Channel Opener ICA-069673 Reveals Subtype-Specific
Functional Roles in Guinea Pig Detrusor Smooth Muscle Excitability and Contractility. The Journal of pharmacology and experimental
therapeutics, 2015. 354(3): p. 290-301.
Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics. All rights reserved
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of the KV7 channel inhibitor XE991. Unlike nifedipine, under conditions of elevated
extracellular K+ (60 mM), the effects of ICA-069673 on DSM tonic contractions were
significantly attenuated. ICA-069673 decreased global intracellular Ca2+ concentration in
DSM cells, and this effect was blocked by nifedipine. ICA-069673 hyperpolarized the
membrane potential and inhibited DSM spontaneous action potentials of isolated DSM
cells, effects which were blocked in the presence of XE991. In conclusion, the current
study using the novel KV7.2/KV7.3 channel activator ICA-069673, provides strong
evidence for a critical role for the KV7.2- and KV7.3-containing channels in DSM function
at both cellular and tissue levels.
INTRODUCTION
Voltage-gated K+ (KV7) channels (KV7.1-KV7.5), also known as KCNQ (KCNQ1KCNQ5) channels, have recently been suggested as regulators of detrusor smooth muscle
(DSM) excitability and contractility [7-9]. In DSM, the overall function of KV channels,
which includes the KV7 channels, is to maintain and stabilize the resting membrane
potential [4]. This is achieved by limiting the influx of Ca2+ through L-type voltage-gated
Ca2+ (CaV) channels, which leads to DSM relaxation. The ability for DSM cells to generate
spontaneous action potentials, which underlies DSM phasic contractility, allows this cell
type to facilitate the function of the urinary bladder [4, 10, 11]. Under pathophysiological
conditions such as overactive bladder (OAB), the contractile activity of DSM may be
abnormally increased [12]. Thus, pharmacologically targeting bladder-specific KV7
channel subtypes may represent a novel therapeutic strategy to control OAB.
The KV7 channel family consists of five members (KV7.1-KV7.5), which form homomic or
heteromeric tetramers of KV7 α-subunits. The diversity of KV7 channel combinations, such
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as KV7.2/KV7.3 or KV7.3/KV7.5, expands their functional and biophysical properties [4,
13, 14]. For example, heteromeric KV7.2/KV7.3 channels produce whole cell currents 10fold higher in amplitude than either homomeric K V7.2 or KV7.3 channels [14]. KV7
channels can also associate with β-regulatory subunits (KCNE1-KCNE5), which may alter
KV7 channel properties and subcellular localization [15, 16]. This diversity of KV7
channels expression and function, underlie their attractiveness as potential novel
therapeutic targets for OAB.
KV7 channel pharmacological modulators have proven useful for elucidating K V7
channel functional roles in various tissues including vascular, bronchial, and
gastrointestinal smooth muscle [17-24]. Such modulators include KV7 channel activators
retigabine (KV7.2-KV7.5) and L-364,363 (KV7.1) as well as KV7 channel inhibitors XE991
and linopiridine, which effectively block all K V7 channels. Potential KV7 channel
functional role in DSM was suggested during the clinical trials of the antiepileptic drug
retigabine. Patients undergoing treatment reported an increased occurrence of urinary
retention compared to the placebo [25]. These findings correspond with in vivo studies in
rodents, where retigabine increased bladder capacity while decreasing voiding frequency
[26, 27].
In guinea pig DSM, mRNA transcripts for all K V7 channel subunits have been
identified [8], with qPCR studies indicating that KV7.1, KV7.2, and KV7.5 channel αsubunits are most prevalent in DSM cells [7]. KV7 channel inhibition with XE991 was
associated with membrane depolarization and an increase in Ca2+ oscillations and phasic
contractions in guinea pig DSM [7, 8]. KV7 channel activation with retigabine caused
membrane hyperpolarization and inhibition of DSM phasic contractions [7]. KV7 channels
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also regulate porcine DSM contractility, where the KV7.2 and KV7.4 channel activator
ML213 displayed a comparable effect to retigabine in promoting DSM relaxation [28].
Despite emerging developments, KV7 channel subtype-specific physiological roles remain
poorly understood due to the lack of selective pharmacological modulators capable of
distinguishing among KV7 channel subtypes [29].
The novel compound N-2-chloro-5-pyrimidinyl-3,4-difluorobenzamide (ICA069673) was developed by Icagen, Inc. (Durham, NC) – now part of Pfizer as Neusentis –
in a screening program to identify subtype-selective KV7 channel activators [30]. ICA069673 demonstrated 20-fold greater selectivity for heteromeric KV7.2/KV7.3 channels
over KV7.3/KV7.5 with EC50 values of 0.69 µM and 14.3 µM, respectively [30]. ICA069673 did not affect KV7.1 channels, which are predominately expressed in the heart [30].
A recent study on A7r5 smooth muscle cell line demonstrated that ICA-069673 was
effective in activating recombinantly expressed K V7.4 channels [31]. However, as KV7.4
channel protein expression was not observed in guinea pig DSM [7], its functional
relevance in DSM is unlikely.
Here, we aimed to investigate the functional roles of K V7.2- and KV7.3-containing
channels in DSM excitability and contractility by targeting them with the novel
KV7.2/KV7.3 channel activator ICA-069673. We applied a multi-level experimental
approach including immunocytochemistry with confocal microscopy, Western blot,
isometric DSM tension recordings, Ca2+ imaging, and perforated whole cell patch-clamp
electrophysiology to test the hypothesis that K V7.2- and KV7.3-containing channels are
among the KV7 channel subtypes regulating DSM excitation-contraction coupling.
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MATERIALS AND METHODS
Ethical approval for animal use. Experimental procedures involving the use of animals,
as described in this study, were reviewed and approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of South Carolina (Columbia, SC, USA),
protocol #1747.
Animal housing, euthanasia, and DSM tissue acquisition. A total of 38 adult male
Hartley-Albino guinea pigs, ages ranging 3-12 months (Charles River Laboratories,
Raleigh, NC, USA) and weights 310-575 g (average 463±16 g) were used in the present
studies. Animals were housed at room temperature (22-23 ºC) within the Animal Resource
Facilities at the University of South Carolina. Guinea pigs had free access to food and water
and were exposed to 12 h light/dark cycles. Each animal was euthanized by CO2 inhalation
using a SMARTBOX™ Automated CO2 Delivery System (Euthanex Corp, Palmer, PA,
USA) followed by thoracotomy. The urinary bladder was subsequently removed by
administering a transverse incision superior to the bladder neck.
DSM single-cell isolation and collection. DSM single cells were enzymatically isolated
using a combination of papain and collagenase as previously described [7]. DSM cells were
used for Ca2+ imaging or electrophysiological experiments within 12 h after isolation.
Intact DSM strips with urothelium removed were used for single cell isolation.
Western blot analysis. Western blot experiments were performed according to previously
described methods [10, 32]. For these experiments, the primary antibodies used were the
anti-KCNQ2 (KV7.2) (1:200 dilution, Santa Cruz Biotechnology, Dallas, TX, USA, cat.
number: sc-7793) or anti-KCNQ3 (KV7.3) (1:200 dilution, Santa Cruz Biotechnology, cat.
number: sc-7794) polyclonal antibodies, respectively. The donkey anti-goat IgG-HRP
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secondary antibody (1:500 dilution, Santa Cruz Biotechnology, cat. number: sc-2020) was
used for all Western blot experiments. Experiments utilizing the competing peptides for
KV7.2 (Santa Cruz Biotechnology, cat. number: sc-7793P) or KV7.3 (Santa Cruz
Biotechnology, cat. number: sc-7794P) were pre-incubated with the KV7.2 or KV7.3
primary antibodies, respectively.
Immunocytochemistry. Immunocytochemical studies were conducted as previously
described [10, 32]. Freshly-isolated DSM cells were incubated using either the antiKCNQ2 (KV7.2) primary antibody (1:300 dilution, Santa Cruz Biotechnology, cat.
number: SC-7793), or the anti-KCNQ3 (KV7.3) primary antibody (1:300 dilution, Santa
Cruz Biotechnology, cat. number: SC-7795-R) diluted in 1% BSA/PBS overnight at 4°C.
DSM cells that were incubated with the anti-KV7.2 goat polyclonal antibody were then
incubated with the secondary antibody Cy3-AffiniPure donkey anti-goat IgG (1:500
dilution; cat. number: 705-165-147, Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA) overnight at 4°C. DSM cells that were incubated with the anti-KV7.3
rabbit polyclonal primary antibody were then incubated with the secondary antibody Cy5AffiniPure donkey anti-rabbit IgG (1:500 dilution; cat. number: 711-175-152, Jackson
ImmunoResearch Laboratories, Inc.) overnight at 4°C. Subsequently, DSM cells were
incubated in phosphate buffered saline (PBS) with the α-smooth muscle actin fluorescein
isothiocyanate (FITC) antibody (cat. number: F3777, Sigma-Aldrich) for 2 h in a dark
room. Nuclear staining was achieved by incubating DSM cells for 15 min in 4′,6diamidino-2-phenylindole (DAPI, Invitrogen, Ltd., Grand Island, NY, USA; diluted in
PBS 1:10,000). DSM cells were mounted with 1,4-Diazabicyclo[2.2.2]octane (DABCO).
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Confocal images were obtained with a 63x oil immersion objective using a laser scanning
LSM 700 confocal microscope (Carl Zeiss, Germany).
Isometric DSM tension recordings. Isometric DSM tension recordings were performed
as previously described using DSM isolated strips free from urothelium [7, 10, 32, 33]. In
urothelium-denuded DSM isolated strips showing spontaneous phasic contractions, the
neuronal Na+ channel blocker tetrodotoxin (TTX, 1 µM) was included prior to the
application of increasing concentrations of ICA-069673 (100 nM-30 µM). Two separate
protocols were conducted involving electric field stimulation (EFS)-induced DSM
contractions, which were performed in the absence of TTX using a PHM-152I
programmable stimulator (Med Associates, Inc., Georgia, VT, USA). For the first protocol,
continuous stimulation of 10 Hz EFS frequency was delivered at 1 min intervals and a
stable baseline and amplitude were reached prior to applying increasing concentrations of
ICA-069673 (100 nM-30 µM). In the second EFS protocol, we applied incremental EFS
stimulation frequencies (3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz) at 3 min intervals for
a control period, and then again in the presence of a single concentration of ICA-069673
(either 3 µM or 10 µM).
Ratiometric fluorescence Ca2+ imaging in freshly-isolated guinea pig DSM cells. We
measured the global intracellular Ca2+ levels of freshly-isolated DSM cells using fura-2
AM, a ratiometric fluorescent Ca2+ probe, in accordance with previously described
procedures [32].
Whole cell patch-clamp electrophysiology. Amphotericin-B perforated whole cell patchclamp experiments were performed in current-clamp mode as previously described [7, 32].
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All patch-clamp electrophysiological experiments were conducted at room temperature
(22-23°C).
Solutions and drugs. Ca2+-free dissection solution was composed of each of the following
(in mM): 80 monosodium glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 4-(2hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES); 2 MgCl2; NaOH was used to
attain pH 7.3. PSS solution containing Ca2+ was freshly prepared each day and contained
the following (in mM): 119 NaCl; 4.7 KCl; 24 NaHCO 3; 1.2 KH2PO4; 2.5 CaCl2; 1.2
MgSO4; 11 glucose; that was aerated with 95% O2/5% CO2 to attain pH 7.4. Physiological
bath solution utilized for patch-clamp experiments was composed of the following (in
mM): 134 NaCl; 6 KCl; 1 MgCl2; 2 CaCl2; 10 glucose; 10 HEPES; and NaOH was used
to obtain pH 7.4. The patch-pipette solution contained (in mM): 110 potassium aspartate;
30 KCl; 10 NaCl; 1 MgCl2; 10 HEPES; 0.05 ethylene glycol-bis(2-aminoethylether)N,N,N',N'-tetraacetic acid (EGTA); NaOH was used to adjust the pH to 7.2. AmphotericinB stock solution was freshly prepared daily in dimethyl sulfoxide (DMSO) and was
included in the pipette solution (200-300 μg/ml) before the experiment and was
subsequently replaced every 1-2 h. ICA-069673, XE991, fura-2 AM, and TTX were
purchased from Tocris Bioscience (Minneapolis, MN) and were dissolved in DMSO,
double distilled water, and acetate buffer at pH 4.8, respectively. Nifedipine was purchased
from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in DMSO.
Data Analysis and Statistics. Isometric DSM tension recording experiments were
conducted using MyoMed software and analyzed as previously described[7]. Data for
isometric DSM tension were normalized and expressed in %. For spontaneous phasic,
carbachol-induced, KCl-induced, and 10 Hz EFS-induced contractions, the 5 min period
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preceding the first application of ICA-069673 (100 nM-30 µM) was taken as the control
(100 %). Maximal efficacy values were normalized to the control, with 0% of the control
indicating full inhibition. The effects of ICA-069673 (100 nM-30 µM) on DSM phasic
contraction parameters were determined by analysis of the 5 min period preceding the
subsequent addition of a higher concentration. In 3.5-50 Hz EFS-induced contractions, the
control period was defined as the contraction amplitude observed at 50 Hz EFS frequency
before the addition of ICA-069673 (3 or 10 µM) and taken as 100%. Perforated whole cell
patch-clamp experiments were performed and analyzed using pCLAMP 10.2. When ICA069673 was applied in the presence of XE991, the control was defined as the 5 min period
before the addition of ICA-069673 (in the presence of XE991 only). Where indicated in
the summarized data, n represents the number of freshly-isolated DSM strips or cells, or
individual immunocytochemistry/Western blot experiments, and N represents the number
of guinea pigs. For spontaneous contraction experiments, statistical analysis for the
comparison of ICA-069673 in the absence or presence of XE991, two-way ANOVA test
was performed followed by Bonferroni post-hoc test. Remaining statistical analyses were
performed using a two-tailed paired Students t-test. Summarized data are reported as
means±SEM. P values <0.05 were considered statistically significant. Corel Draw Graphic
Suite X3 software (Corel Co., Mountain View, CA) and GraphPad Prism 4.03 software
(La Jolla, CA) was used for data illustration.
RESULTS
KV7.2- and KV7.3-containing channels are expressed in freshly-isolated DSM cells. To
determine the protein expression of KV7.2 and KV7.3 channel subunits and their subcellular
localization in DSM cells, we performed Western blot and immunocytochemical
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experiments, respectively. Western blot data revealed the protein expression of K V7.2 and
KV7.3 channel subunits in whole DSM tissue, which were not observed when the
competing peptides for each KV7.2 and KV7.3 channel-specific antibodies were present
(n=3, N=3, Figure 3.1). In freshly-isolated DSM cells, immunocytochemical experiments
were conducted using antibodies specific for K V7.2 or KV7.3 channel subunits in
combination with the α-smooth muscle actin-FITC antibody and DAPI nuclear stain
(Figure 3.1). The data demonstrated that KV7.2 and KV7.3 channel subunits are expressed
in DSM cells and localized within the vicinity of the cell membrane (n=3, N=3, Figure
3.1). The detection of KV7.2 and KV7.3 channel protein expression in isolated DSM cells
was abolished when the competing peptides for the K V7.2 or KV7.3 channel-specific
antibodies were present (Figure 3.1). This confirms the specificity of the KV7.2 and KV7.3
channel-specific antibodies used in this study.
The Kv7.2/Kv7.3 chnanel activator ICA-069673 induces inhibition of spontanous
phasic contrations in DSM isolated strips. In order to determine the functional roles of
the KV7.2/KV7.3 channels on spontaneous phasic contractions in guinea pig DSM isolated
strips, we conducted isometric DSM tension recordings using the novel K V7.2/KV7.3 novel
activator ICA-069673. As shown in Figure 3.2, ICA-069673 (100 nM-30 µM) caused a
concentration-dependent inhibition of spontaneous phasic contractions, an effect that
recovered upon washout of ICA-069673. The IC50 and maximal efficacy values for ICA069673 on spontaneous phasic DSM contraction parameters were the following:
contraction amplitude, 4.5 (2.6-7.9, 95% confidence interval) µM and 3.3±1.8% of precompound control; muscle force integral, 3.2 (2.0-5.2) µM and 2.2±1.4%; contraction
duration, 8.6 (4.3-17.3) µM and 9.8±5.2%, respectively. The IC50 value for the effect of
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ICA-069673 on contraction frequency was 11.9 µM. The effect of ICA-069673 on
contraction frequency resulted in maximal reduction of contraction frequency to
25.2±14.1% of the control (n=11, N=7; P<0.05; Figure 3.2). To confirm that
concentration-dependent inhibition of spontaneous phasic contractions caused by ICA069673 was mediated by KV7 channels, we examined its effects in the presence of the KV7
channel inhibitor XE991 (10 µM). In the presence of XE991 (10 µM), there were no
measureable inhibitory effects of ICA-069673 on DSM phasic contractions (n=12, N=6;
P>0.05; Figure 3.2). These results support the concept that KV7.2- and KV7.3-containing
channels are important physiologically-relevant mediators of spontaneous phasic
contractions in DSM isolated strips.
The Kv7.2/Kv7.3 chnanel activator ICA-069673 inhibits pharmacologically-induced
contractions in DSM isolated strips. We examined the effects of ICA-069673 on DSM
phasic contractions induced in response to either muscarinic receptor activation or
sustained membrane potential depolarization using carbachol or KCl, respectively. ICA069673 (100 nM-30 µM) caused a concentration-dependent inhibition of 0.1 µM
carbachol-induced DSM contractions. For 0.1 µM carbachol-induced contractions, the IC50
and maximal efficacy values of ICA-069673 were: contraction amplitude, 5.5 (3.0-10.2,
95% confidence interval) µM and 20.8±8.9%; muscle force integral, 3.6 (1.9-7.0) µM and
18.9±8.2%; contraction duration, 13.3 (6.3-28.2) µM and 36.4±14.9%, respectively. DSM
phasic contraction frequency was maximally reduced to a lesser extent to 46.5±18.2% of
the control (n=10, N=7; P<0.05; Figure 3.3). ICA-069673 (100 nM-30 µM) concentrationdependently inhibited DSM phasic contractions induced by 20 mM KCl. For 20 mM KClinduced contractions, the IC50 and maximal efficacy values for ICA-069673 on DSM
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contraction parameters were as follows: contraction amplitude, 5.3 (2.6-11.0) µM and
10.4±5.6%; and muscle force integral, 4.2 (2.4-7.6) µM and 5.3±3.6%; contraction
duration, 11.1 (2.8-36.7) µM and 31.8±13.0%; and contraction frequency, 12.2 (3.4-44.2)
µM and 22.5±8.9% of the control, respectively (n=7, N=7; P<0.05; Figure 3.4). We then
tested the effects of ICA-069673 (10 μM) on DSM tonic contractions induced by 60 mM
KCl to determine the role of K+ conductance in mediating the inhibitory effects of ICA069673 as well to assess the functional interaction with the L-type CaV channels. As
illustrated in Figure 3.5, under these experimental conditions, ICA-069673 (10 µM)
decreased DSM tone to only 89.2±3.2% of the control (n=8, N=4; P<0.05) while the
subsequent addition of the L-type CaV channel inhibitor nifedipine (1 µM) led to a more
significant reduction in DSM tone to 28.7±3.8% of the control (n=8-9, N=4; P<0.001;
Figure 3.5). There was a statistically significant difference between the inhibitory effects
of ICA-069673 and nifedipine on DSM tonic contraction (n=8-9, N=4; P<0.001). These
experiments support the concept that ICA-069673 does not directly inhibit L-type CaV
channels
The Kv7.2/Kv7.3 chnanel activator ICA-069673 inhibits nerve-evoked contractions in
DSM isolated strips. To assess the effects of ICA-069673 on nerve-evoked DSM
contractions, we applied increasing concentrations of ICA-069673 to continuous 10 Hz
EFS-induced contractions of DSM isolated strips. Under these experimental conditions,
ICA-069673 (100 nM-30 µM) displayed a concentration-dependent inhibitory effect. For
10 Hz EFS-induced contractions, the IC50 and maximal efficacy values for ICA-069673 on
nerve-evoked DSM contraction parameters were as follows: contraction amplitude, 9.8
(1.1-88.0) µM and 16.6±5.2%; and muscle force integral, 7.6 (0.6-97.8) µM and 19.0±5.4%
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Figure 3.1. KV7.2 and KV7.3 channel subunits are expressed in freshly-isolated guinea
pig DSM cells. Western blot analysis reveals the expression of (A) KV7.2 and (B) KV7.3
channel subunits at the protein level in DSM (n=3, N=3). The expected molecular weights
of KV7.2 and KV7.3 channel proteins are 120 and 97 kDa, respectively (indicated by the
arrows). No protein expression was detected in the presence of the competing peptides
(CP) for each KV7.2 and KV7.3 channel antibodies, respectively. Confocal images from
immunocytochemical experiments demonstrate the expression K V7.2 (C) and KV7.3 (E)
channel subunits in freshly-isolated DSM cells along with membrane localization. Red
staining indicates detection of either KV7.2 or KV7.3 channel subunits. Blue staining
depicts the nucleus. Cells stained with the α-smooth muscle actin-FITC antibody are shown
in green. The overlaid image for KV7.2 or KV7.3 with α-smooth muscle actin-FITC
antibody and DAPI nuclear stain is shown at the bottom right. Co-localization of KV7.2 or
KV7.3 with the α-smooth muscle actin-FITC antibody is indicated by the yellow color in
the merged images, respectively. Inclusion of competing peptides for either K V7.2 (D) or
KV7.3 (E) channels resulted in loss of specific staining. Data for all experiments were
confirmed using DSM tissues from at least 3 guinea pigs. Images were acquired with a
Zeiss LSM 700 confocal microscope using a 63x oil objective.
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Figure 3.2. ICA-069673 inhibits spontaneous phasic contractions in DSM isolated
strips. A) An original isometric DSM tension recording illustrating the inhibition of
spontaneous phasic contractions by ICA-069673 (100 nM-30 µM) in a DSM isolated strip.
The DSM contractions recovered upon washout of ICA-069673. B) An original isometric
DSM tension recording illustrating that blocking K V7 channels with its selective inhibitor
XE991 (10 µM) abolished the inhibitory effects of ICA-069673 (100 nM-30 µM) on DSM
spontaneous phasic contractions. C-F) Cumulative concentration-response curves for ICA069673 on DSM phasic contraction amplitude, muscle force, duration, and frequency in
the absence or presence of 10 µM XE991 (see text for potency and maximum efficacy
values). #P<0.05, ##P<0.01, and ###P<0.001 represent statistically significant effects of
ICA-069673 on spontaneous phasic contractions in the absence of XE991 in comparison
to the control level (i.e. 100%) prior to the addition of ICA-069673 (n=11, N=7). *P<0.05,
**P<0.01, and ***P<0.001 represent statistically significant differences between the
effects of ICA-069673 in the absence versus presence of XE991 (n=12, N=6).
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Figure 3.3. ICA-069673 decreases carbachol-induced phasic contractions in DSM
isolated strips. A) An original isometric DSM tension recording of 0.1 µM carbacholinduced phasic contractions in a DSM isolated strip illustrating the concentrationdependent inhibitory effects of ICA-069673 (100 nM-30 µM). B-E) Cumulative
concentration-response curves for ICA-069673 (100 nM–30 µM) on DSM phasic
contraction amplitude (B), muscle force (C), phasic contraction duration (D), and phasic
contraction frequency (E) (n=10, N=7; *P<0.05, **P<0.01, and ***P<0.001); see text for
potency and maximum efficacy values.
of the control, respectively (n=9, N=9; P<0.05; Figure 3.6). Next, EFS-induced
contractions were stimulated over a range of frequencies (3.5-50 Hz) in the absence or
presence of either 3 or 10 μM ICA-069673, respectively. ICA-069673 (3 or 10 μM)
significantly attenuated the amplitude of EFS-induced contractions stimulated at EFS
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Figure 3.4. ICA-069673 decreases 20 mM KCl-induced phasic contractions in DSM
isolated strips. A) An original isometric DSM tension recording illustrating the
concentration-dependent inhibitory effects of ICA-069673 (100 nM-30 µM) on DSM
phasic contractions induced by 20 mM KCl. B-E) Cumulative concentration-response
curves for the effects of ICA-069673 on DSM phasic contraction amplitude (B), muscle
force (C), phasic contraction duration (D), and phasic contraction frequency (E) (n=7,
N=7; *P<0.05, **P<0.01, and ***P<0.001); see text for potency and maximum efficacy
values.
frequencies from 7.5-50 Hz (n=8-18, N=4-10; P<0.05; Figure 3.7). Collectively, these data
support the concept that KV7.2- and KV7.3-containing channels are critical regulators of
nerve-evoked DSM contractions. The Kv7.2/Kv7.3 chnanel activator ICA-069673
decreases the global intracellular Ca2+ levels in freshly-isolated DSM cells. Next, we
sought to determine the effects of ICA-069673 on global intracellular Ca2+ levels in DSM
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Figure 3.5. Differential effects of ICA-069673 and nifedipine on 60 mM KCl
depolarization-induced tonic contraction in DSM isolated strips. A) An original
isometric DSM tension recording illustrating the effects of 10 µM ICA-069673 and 1 µM
nifedipine on a depolarization-induced DSM tonic contraction caused by 60 mM KCl in a
DSM isolated strip. B) Summarized data demonstrating the inhibitory effect of ICA069673 (10 µM) and nifedipine (1 µM) on DSM tonic contraction induced by 60 mM KCl
(n=8-9, N=4; *P<0.05 and n=6-7, N=3; ***P<0.0001, respectively. ###P<0.0001 represents
a statistically significant difference for the comparison of ICA-069673 and nifedpine.
single cells by measuring the ratio of fura-2 AM fluorescent emission at 510 nm with
excitation at 340 and 380 nm. For the control, the average emitted intensity (F340/F380) prior
to ICA-069673 application was 0.470±0.006 (n=11, N=5). At 10 μM ICA-069673, there
was a significant decrease in the F340/F380 ratio to 0.450±0.006 (n=11, N=5; P<0.05; Figure
3.8). To elucidate the mechanism by which ICA-069673 regulates global intracellular Ca2+
concentrations, we studied the effects of ICA-069673 (10 µM) in the presence or absence
of the L-type CaV channel blocker nifedipine (1 µM). In the presence of 1 µM nifedipine,
ICA-069673 (10 µM) had no significant effect on intracellular Ca2+ levels, with the average
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F340/F380 ratio being 0.470±0.008 compared to the control value of 0.480±0.005 (n=11,
N=5; P>0.05; Figure 3.8). These results demonstrate that in guinea pig DSM cells, ICA069673 decreases global intracellular Ca2+ concentrations by an indirect mechanism
involving inhibition of Ca2+ influx through L-type CaV channels, probably due to
membrane hyperpolarization.
ICA-069673 hyperpolarizes the resting membrane potential and inhibits spontaneous
action potentials in freshly-isolated DSM cells. To determine the regulatory roles of
KV7.2/KV7.3 channels on the DSM cell membrane potential, we employed the
KV7.2/KV7.3 channel activator ICA-069673 and the perforated whole cell patch-clamp
technique in current-clamp mode. The effect of ICA-069673 was examined in 7 DSM cells
(N=6), which had mean cell capacitance of 43.4±4.3 pF and membrane potential of 16.8±2.8 mV. Two of these seven DSM cells displayed distinguishable spontaneous action
potentials. These spontaneous action potentials were abolished by ICA-069673 concurrent
with membrane hyperpolarization (Figure 3.9). In all DSM cells, ICA-069673
hyperpolarized the DSM cell membrane potential by 8.3±2.7 mV (n=7, N=6; P<0.05;
Figure 3.9). The ICA-069673-mediated hyperpolarizing effects on the DSM cell
membrane potential were fully reversible upon washout (Figure 3.9). We then examined
the effects of the KV7 channel inhibitor XE991. As illustrated by the original recording in
Figure 3.9 and summarized data in Figure 3.9, XE991 (10 µM) depolarized the DSM cell
membrane potential by 4.9±1.4 mV (P<0.05; n=5, N=5). To further investigate the
mechanism

underlying

ICA-069673-induced

hyperpolarization,

specifically

dependence on KV7 channel subtypes, the effect of this channel modulator
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Figure 3.6. ICA-069673 decreases nerve-evoked contractions stimulated by 10 Hz
EFS in DSM isolated strips. A) An original isometric DSM tension recording representing
the concentration-dependent inhibitory effects of ICA-069673 (100 nM-30 µM) upon
nerve-evoked contractions induced by 10 Hz EFS stimulation in a DSM isolated strip. B)
Cumulative concentration-response curves for the effects of ICA-069673 (100 nM-30 µM)
on DSM contraction (B) amplitude and (C) muscle force integral (n=9, N=9; **P<0.01,
and ***P<0.001); see text for potency and maximum efficacy values.
was examined in DSM cells pretreated with XE991 (10 µM). The subsequent addition of
ICA-069673 in the continued presence of XE991 did not have a significant hyperpolarizing
effect on the membrane potential of DSM cells (n=7, N=5; P>0.05; Figure 3.9). There was
a statistically significant difference in the effects of ICA-069673 in the absence versus
presence of XE991 (n=5-7, N=5-6; P<0.05; Figure 3.9). Collectively, these data supports
the novel concept that KV7.2- and KV7.3-containing channels are key regulators of DSM
cell excitability.
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Figure 3.7. ICA-069673 decreases 3.5-50 Hz EFS-induced contractions in DSM
isolated strips. A-C) The original isometric DSM tension recordings of 3.5-50 Hz EFSinduced contractions in DSM isolated strips A) before (control) and after the addition of
B) 3 µM ICA-069673 and C) 10 µM ICA-069673. D-E) Cumulative concentrationresponse curves demonstrating the effects of D) 3 µM ICA-069673 and E) 10 µM ICA069673 on the amplitude of 3.5-50 Hz EFS-induced contractions (n=8-18, N=4-10;
*P<0.05, **P<0.01, and ***P<0.001).
DISCUSSION
The present study sought to elucidate the physiological roles of K V7.2- and KV7.3containing channels in DSM excitability and contractility by targeting their activity with
the novel selective KV7.2/KV7.3 channel activator ICA-069673. This was achieved by
applying a multi-level experimental approach at both cellular and tissue levels in DSM.
Western blot analysis detected protein expression for KV7.2 and KV7.3 channel subunits in
DSM tissue. In isolated DSM cells, immunocytochemical experiments further revealed
protein expression for KV7.2 and KV7.3 channel subunits localized within the vicinity of
the cell membrane.
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Figure 3.8. ICA-069673 decreases global intracellular Ca2+ levels in freshly-isolated
DSM cells. A) Original recordings illustrating that ICA-069673 (10 µM) significantly
decreased global intracellular Ca2+ levels in a freshly-isolated DSM cell. B) Summarized
data representing the reduction in global intracellular Ca2+ levels by 10 µM ICA-069673
(n=11, N=5; *P<0.05). C) An original recording representing the lack of effect of ICA069673 (10 µM) in decreasing global intracellular Ca2+ levels in the presence of the L-type
CaV channel blocker nifedipine (1 µM) in a DSM cell. D) Summarized data representing
the effects of ICA-069673 (10 µM) on global intracellular Ca2+ in the presence of
nifedipine (1 µM) (n=10, N=4; P>0.05) in DSM cells. Data are reported as the ratio of fura2 AM fluorescent emission at 510 nm with excitation at 340 and 380 nm; ns, nonsignificant.
Pharmacological studies demonstrated that ICA-069673 significantly hyperpolarized the
membrane potential, inhibited DSM spontaneous action potentials, and decreased global
intracellular Ca2+ concentrations of DSM cells. Functional studies on DSM contractility
revealed that ICA-069673 inhibits spontaneous, pharmacologically-induced, and nerveevoked contractions in DSM isolated strips.
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The inhibitory effects of ICA-069673 on DSM excitability and contractility were
attenuated by the KV7.1-KV7.5 inhibitor XE991, supporting the involvement of K V7
channel subtypes in the regulation of DSM excitability and contractility. Our combined
results suggest a critical role for KV7.2- and KV7.3-containing channels in DSM excitationcontraction coupling.
From all KV7 channel subunits, mRNA transcripts for K V7.1 and KV7.2 channels
are most predominant in guinea pig DSM cells [7]. The expression of KV7 channels at the
protein-level has only been identified in DSM tissue via immunohistochemistry [7, 8],
which has the inherent limitation of potentially detecting K V7 channel expression from
neighboring non-DSM cell types such as neurons or interstitial cells in the absence of cellspecific labelling. Thus, as illustrated in Figure 3.1, novel immunocytochemical
experiments with confocal microscopy reveal the expression of K V7.2- and KV7.3containing channels in isolated DSM cells, where these channels localize within the
vicinity of the cell membrane. Further, Western blot experiments detected protein
expression for both KV7.2 and KV7.3 channel subunits in DSM (Figure 3.1), consistent
with the previous reports by our group and others using immunohistochemistry [7, 8].
KV7 channel activators and inhibitors such as retigabine and XE991 have provided a useful
pharmacological approach for elucidating KV7 channel roles in urinary bladder function
[4, 7-9, 26-28, 34]. However, retigabine and XE991 do not effectively distinguish among
KV7.2-KV7.5 and KV7.1-KV7.5 channel subtypes, respectively.
The lack of subtype selectivity of these pharmacological modulators has thus been
a substantial limitation for gaining an improved understanding of the KV7 channel subtypes
most critical to DSM function. A novel K V7 channel activator, ICA-069673, has
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demonstrated selectivity for heteromeric KV7.2/KV7.3 channels and is a pyrimidine
analogue of N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243) [30, 35, 36].
Though less potent than its related analog ICA-27243, ICA-069673 displays greater
efficacy and improved selectivity for heteromeric K V7.2/KV7.3 over KV7.1 channels [30].
In contrast to retigabine, which binds to the pore region (S5-S6) of KV7.2-KV7.5 channels
[37], evidence suggests that ICA-069673 is among an emerging novel class of compounds
known as “gating modifiers”, named so for their ability to bind to the S1-S4 voltagesensing domain of KV7 channels [31, 36, 38]. The functional studies on DSM contractility
revealed that ICA-069673 effectively inhibited spontaneous phasic contractions in DSM
isolated strips in a concentration-dependent manner (Figure 3.2). Occurring locally in
DSM, spontaneous phasic contractions do not initiate urine voiding; however, these
contractile events have been associated with involuntary non-voiding contractions
observed in some forms of OAB [11, 12]. The inhibition of DSM contractility was not
observed when ICA-069673 was administered in the presence of the KV7 channel inhibitor
XE991, which indicates the inhibitory effects of ICA-069673 on spontaneous phasic
contractions were mediated by KV7 channels (Figure 3.2).
Similarly, DSM phasic contractions induced by the muscarinic receptor agonist
carbachol (0.1 µM) or through slight membrane depolarization by KCl (20 mM) were
significantly inhibited by ICA-069673. Under conditions of high extracellular K+ (60 mM),
which significantly changes the driving force for K+ and causes sustained membrane
depolarization that in turn activates the L-type CaV channels, ICA-069673 (10 µM) had a
rather modest inhibitory effect on DSM tone (~10% of the maximum relaxation, Figure
3.5). In contrast, the subsequent inhibition of L-type CaV channels using nifedipine
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decreased DSM tonic contractions by approximately seven -fold in comparison to ICA069673 alone (Figure 3.5).
These results support the concept that ICA-069673 does not directly inhibit L-type
CaV channels in DSM. These data are consistent with a previous report where ICA-069673
(30 µM) demonstrated no direct effects on L-type CaV channels, as well as voltage-gated
Na+ (Nav1.5), hERG, KV7.1, or GABAA channels at 10 µM [30]. We next examined how
ICA-069673 affects nerve-evoked DSM contractions induced by EFS. The results showed
that ICA-069673 significantly decreased 10 Hz EFS-induced contractions (Figure 3.6) and
contractions induced over a large range of EFS frequencies (3.5-50 Hz) (Figure 3.7),
indicating that KV7.2- and KV7.3-containing channels sensitive to ICA-069673 are
essential regulators of urinary bladder nerve-evoked contractions. Qualitatively, the effects
of ICA-069673 on DSM contractility were consistent with those reported for retigabine
[7]. This similarity suggests the involvement of the same molecular targets by retigabine
and ICA-069673, indicating a prominent role for the KV7.2- and KV7.3-containing
channels in DSM function.
The contraction of DSM is ultimately triggered in response to a rise in the
intracellular Ca2+ concentration [1]. Therefore, we sought to determine the effects of ICA069673 on global intracellular Ca2+ levels and to elucidate the role of the KV7.2/KV7.3
channels in controlling DSM cell Ca2+ signaling by conducting ratiometric fluorescence
Ca2+ imaging on isolated DSM cells. ICA-069673 (10 µM) significantly decreased global
intracellular Ca2+ levels in DSM cells (Figure 3.8), consistent with the inhibitory effects
of ICA-069673 on DSM contractility. The reduction of intracellular Ca2+ concentrations
by ICA-069673 is in agreement with the opposite phenomenon where the KV7 channel
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inhibitor XE991 increased the frequency of Ca2+ oscillations in DSM tissue [8]. To further
assess the interactions of the KV7.2/KV7.3 channels with the L-type CaV channels, we
investigated the effects of ICA-069673 in the presence of the L-type CaV channel blocker
nifedipine (1 µM). The results showed that when L-type CaV channels were inhibited by
nifedipine, ICA-069673 had no effect on global intracellular Ca2+ levels (Figure 3.8).
These observations support the concept that in isolated DSM cells, ICA-069673 reduces
global intracellular Ca2+ levels by inhibiting L-type CaV channels indirectly through
activation of KV7.2- and KV7.3-containing channels and associated membrane
hyperpolarization.
Our group was the first to record spontaneous action potentials in freshly-isolated
DSM cells and to report the effects of retigabine on the action potentials using the
perforated patch-clamp technique in current-clamp mode [7]. The current study revealed
that ICA-069673 (10 µM) hyperpolarized the membrane potential and inhibited
spontaneous action potentials in isolated DSM cells (Figure 3.9). The hyperpolarizing
effects of ICA-069673 on the DSM cell membrane potential were comparable to that of
retigabine [7]. ICA-069673-mediated hyperpolarization was blocked when the K V7
channels were inhibited by XE991 (Figure 3.9). XE991 alone induced depolarization as
measured with the perforated patch-clamp technique (Figure 3.9) consistent with a
previous finding using the conventional whole cell patch-clamp technique [8]. The
combined results from our patch-clamp studies indicate a key role for K V7.2- and KV7.3containing channels in regulating spontaneous action potentials and the resting membrane
potential of isolated DSM cells.
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In conclusion, the current study using the novel K V7.2/KV7.3 channel activator
ICA-069673, provides strong evidence to suggest a critical role for the K V7.2- and KV7.3containing channels in DSM function at both cellular and tissue levels. Pharmacological
activation of KV7.2/KV7.3 channels with ICA-069673 hyperpolarized the membrane
potential and inhibited spontaneous action potentials in freshly-isolated DSM cells
preventing Ca2+ influx through L-type CaV channels to reduce global intracellular Ca2+
concentrations, and caused relaxation of DSM isolated strips.
While our study demonstrates important roles for KV7.2- and KV7.3-containing
channels in DSM cells and tissue, evidence suggests a prominent role for K V7.4 and KV7.5
channels in non-DSM human smooth muscle tissues [22, 39, 40]. Therefore, it is important
for future studies to investigate the expression and function of K V7 channels in human
DSM at both the whole tissue and single-cell levels, which is critical for further evaluating
their therapeutic potential as novel targets for the treatment of OAB.
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Figure 3.9. ICA-069673 hyperpolarizes the resting membrane potential and inhibits
spontaneous action potentials in freshly-isolated DSM cells. A) An original membrane
potential recording in current-clamp mode of a DSM cell exhibiting spontaneous action
potentials. ICA-069673 (10 µM) hyperpolarized the DSM cell membrane potential and
further abolished the spontaneous action potentials in a manner reversible upon washout.
B) An original membrane potential recording of a DSM cell that does not exhibit
spontaneous action potentials. ICA-069673 (10 µM) hyperpolarized the membrane
potential, an effect which was recovered upon washout. C) An original membrane potential
recording illustrating that the KV7 channel inhibitor XE991 (10 µM) depolarized the DSM
cell membrane potential. D) A continuation of the recording in (C) illustrating that in the
presence of XE991 (10 µM), the hyperpolarizing effects of ICA-069673 (10 µM) on the
DSM cell membrane potential are attenuated. E) Summarized data for the effects of ICA069673 (10 µM), washout of ICA-069673, XE991 (10 µM), and ICA-069673 (10 µM) in
the presence of XE991 (10 µM) on the membrane potential. The Y-axis represents the
change in the membrane potential, either depolarization (+) or hyperpolarization (-). With
the exception of when ICA-069673 was applied in the presence of XE991, the control
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period was in the absence of any pharmacological treatment. When determining the effects
of ICA-069673 in the presence of XE991, the control was the 5-min period of stable
recording before the addition of ICA-069673 (i.e. in the presence of XE991 only). *
indicates statistical difference of P<0.05 versus the control for the treatments shown; #
P<0.05 and ## P<0.01 indicate statistically significant differences for the comparisons
shown. Each data-point in (E) is n=5-7, N=5-6.
Table 3.1. IC50 and maximal efficacy values for the effects of ICA-069673 on
spontaneous phasic, pharmacologically-induced, and 10 Hz EFS-induced
contractions in guinea pig DSM isolated strips. IC50: Mean (95% confidence interval),
Maximal efficacy: Mean±SEM. n/a, not applicable. *Maximum efficacy is normalized to
the control on a scale from 100% (no relaxation) to 0% (full relaxation).
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CHAPTER 4
7

KV7 CHANNEL PHARMACOLOGICAL ACTIVATION WITH THE NOVEL
ACTIVATOR ML213: ROLE FOR HETEROMERIC KV7.4/KV7.5 CHANNELS IN
GUINEA P IG DETRUSOR SMOOTH MUSCLE FUNCTION
ABSTRACT
Voltage-gated KV7 channels (KV7.1-KV7.5) are important regulators of the cell membrane
potential in detrusor smooth muscle (DSM) of the urinary bladder. This study sought to
further the current knowledge of KV7 channel function at the molecular, cellular, and tissue
levels in combination with pharmacological tools. We used isometric DSM tension
recordings, ratiometric fluorescence Ca2+ imaging, amphotericin-B perforated patch-clamp
electrophysiology, and in situ proximity ligation assay (PLA) in combination with the
novel

compound

N-(2,4,6-Trimethylphenyl)-bicyclo[2.2.1]heptane-2-carboxamide

(ML213), an activator of KV7.2, KV7.4 and KV7.5 channels, to examine their physiological
roles in guinea pig DSM function. ML213 caused a concentration-dependent (0.1-30 µM)
inhibition of spontaneous phasic contractions in DSM isolated strips; effects blocked by
the KV7 channel inhibitor XE991 (10 µM). ML213 (0.1-30 µM) also reduced
pharmacologically-induced and nerve-evoked contractions in DSM strips. Consistently,
ML213 (10 µM) decreased global intracellular Ca2+ concentrations in fura-2 loaded DSM
isolated strips. Perforated patch-clamp electrophysiology revealed ML213 (10 µM) caused
an increase in the amplitude of whole cell K V7 currents. Further, in current-clamp mode of

7

Provence A, Angoli D, Petkov GV. KV7 Channel Pharmacological Activation with the Novel Activator ML213: Role for Heteromeric
KV7.4/KV7.5 Channels in Guinea Pig Detrusor Smooth Muscle Function. J Pharmacol Exp Ther. 2017 Oct 30. pii: jpet.117.243162.
Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics. All rights reserved.

40

the perforated patch-clamp, ML213 hyperpolarized DSM cell membrane potential in a
manner reversible by washout or XE991 (10 µM), consistent with ML213 activation of
KV7 channel currents. Pre-application of XE991 (10 µM) not only depolarized the DSM
cells, but also blocked ML213-induced hyperpolarization, confirming ML213 selectivity
for KV7 channel subtypes. In situ PLA revealed co-localization and expression of
heteromeric KV7.4/KV7.5 channels in DSM isolated cells. These combined results suggest
that ML213-sensitive KV7.4-and KV7.5-containing channels are essential regulators of
DSM excitability and contractility.
INTRODUCTION
Voltage-gated KV7 channels (KV7.1-KV7.5), encoded by KCNQ genes (KCNQ1KCNQ5), are critically involved in establishing and maintaining the cell membrane
potential of many excitable cells and tissue types [17, 20-22, 24, 40, 41]. In addition,
emerging new evidence points to potential physiological roles for the K V7 channels in
detrusor smooth muscle (DSM), the main muscular component of the urinary bladder [79, 26, 28, 34, 40, 42, 43].
Recent studies from our laboratory and others show that K V7 channels serve key
functional roles in regulating DSM function in rats [28, 34], guinea pigs [7, 8, 42], pigs
[28], and humans [9, 44]. KV7 channel activation leads to hyperpolarization of the
membrane potential thereby decreasing Ca2+-influx through L-type voltage-gated Ca2+
channels, which precludes Ca2+-dependent activation of myosin light chain kinase
necessary for initiation of DSM contractility [4, 40]. KV7 channels were initially termed
“M channels” as pioneering studies in frog sympathetic neurons demonstrated the
suppression of KV7 channel currents in response to Gq/11-coupled muscarinic acetylcholine
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receptor (mAChR) activation [45]. However, whether mAChRs are involved in the
regulation of KV7 channel activity in DSM is not known.
KV7 channel pore-forming α-subunits (KV7.1-KV7.5) have been shown to form
both homo- and heteromeric channel conformations in experimental cell lines and native
biological systems, which significantly expands the molecular and functional diversity of
the KV7 channel family [15, 16]. Further, KV7 channel expression and function have also
been shown to follow a certain level of subtype- and tissue-specificity. For example, KV7.1
channels have established roles in the termination of the cardiac action potential [46],
heteromeric KV7.2/KV7.3 channels underlie the neuronal “M-current” [47], and homo- or
heteromeric combinations of KV7.4 and KV7.5 channel subtypes appear most critical in
smooth muscle function [48]. Understandably, the development of novel KV7 channel
pharmacological modulators with improved selectivity to distinguish among individual
KV7 channel subtypes, is a highly sought endeavor. Indeed, several K V7 channel
pharmacological modulators have emerged in recent years displaying improved selectivity
for individual KV7 channel subtypes, including the KV7.2/KV7.3 channel activator ICA069673, a potent inhibitor of DSM excitability and contractility [42].
The compound N-(2,4,6-Trimethylphenyl)-bicyclo[2.2.1]heptane-2-carboxamide
(ML213) is a novel KV7 channel activator initially characterized as being selective for
KV7.2 and KV7.4 channel subtypes displaying ~80-fold selectivity over other KV7 channels
[49, 50], as well as greater potency than other Kv7 activators such as retigabine and
BMS204352 [23]. Subsequent in vitro pharmacological and electrophysiological studies in
A7r5 vascular smooth muscle cells have reported ML213 as a potent activator of
homomeric KV7.4 and KV7.5 channels and heteromeric KV7.4/KV7.5 channels [31].
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ML213 is currently the only known K V7 channel activator with this unique
pharmacological selectivity profile. Nonetheless, studies seeking to identify whether
heteromeric KV7 channels, specifically heteromeric KV7.4/KV7.5 channels, are expressed
in DSM are currently absent. To identify the potential ML213-sensitive KV7 channel
conformations expressed at the cellular level in DSM would greatly enhance our
understanding of ML213 pharmacological effects on DSM function, while expanding our
knowledge of the physiological roles of KV7 channel subtypes in the urinary bladder.
Here, we used the novel KV7 channel activator ML213 to reveal insights into the
subtype-specific KV7 channel functional roles in DSM excitability and contractility. This
was achieved by a multidisciplinary experimental approach using isometric DSM tension
recordings, ratiometric fluorescence Ca2+ imaging, and amphotericin-B perforated patchclamp electrophysiology. Further, in situ proximity ligation assay (PLA) was conducted to
elucidate whether KV7.4 and KV7.5 channels, key pharmacological targets of ML213, colocalize to form heteromeric channel complexes in DSM cells.
MATERIALS AND METHODS
Ethical approval for animal use. Protocols for the use of experimental animals in the
current study are consistent with the NIH guidelines for the care and use of experimental
animals and were reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of South Carolina, protocols #2186-100859-072114
and #2321-101157-092116.
Animal housing, euthanization, and DSM tissue acquisition. 41 adult male HartleyAlbino guinea pigs (Charles River Laboratories, Raleigh, NC, USA), aged 3-12 months
and weighing 341-1,191 g (average 902±10 g), were utilized for this study. Animals were
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housed in the Animal Resource Facilities at the University of South Carolina where they
had free access to food and water and were exposed to 12 h light/dark cycles at room
temperature (22-23 ºC). Animals were euthanized via CO2 inhalation using a
SMARTBOX™ Automated CO2 Delivery System (Euthanex Corp, Palmer, PA, USA),
followed by thoracotomy. The urinary bladder was then removed by an incision superior
to the bladder neck. Following dissection, the urinary bladder is cut open via a longitudinal
incision originating from the urethral orifice. This allows the bladder to be opened and
pinned down flat to the base of a Sylgard-coated Petri dish. Under a dissection microscope,
microscissors in combination with forceps are used to remove not only the urothelium, but
the entire mucosal layer and lamina propria from the detrusor.
DSM cell isolation and collection. DSM single cells were freshly isolated using a
combination of papain and collagenase as previously described [51]. DSM cells were used
for electrophysiological experiments or in situ PLA within 12 h after isolation. Intact DSM
strips with urothelium removed were used for single cell isolation, isometric DSM tension
recordings, and ratiometric fluorescence Ca2+ imaging.
Isometric DSM tension recordings. Isometric DSM tension recordings were conducted
as previously described on isolated DSM strips void of urothelium [51]. For experiments
on spontaneous phasic, carbachol (CCh)-induced, and KCl-induced contractions, the DSM
isolated strips were pretreated with the neuronal voltage-gated Na+ channel blocker
tetrodotoxin (TTX, 1 µM) before the concentration-response effects of ML213 (0.1-30
µM) were assessed. Electrical field stimulation (EFS)-induced DSM contractions were
stimulated with a PHM-152I programmable stimulator (Med Associates, Inc., Georgia,
VT, USA) in the absence of TTX. Ten or twenty Hz EFS frequency, respectively, was
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delivered at 1 min intervals and ML213 (0.1-30 µM) was administered once a stable
baseline and contraction amplitude was achieved. In a separate protocol, EFS-induced
DSM contractions were stimulated at 3 min intervals over a wide range of frequencies (0.5,
2.0, 3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz) in the absence (control) and then in the
presence of ML213 (1 or 3 µM). The inhibitory effects of ML213 were normalized to the
control (taken to be 100%) and expressed as percentages, with 100% indicated no effect
and 0% indicated complete DSM relaxation.
Ratiometric fluorescence Ca2+ imaging. Global intracellular Ca2+ concentrations of
isolated DSM strips were measured using the ratiometric fluorescence Ca2+ probe fura-2
AM as previously described [32, 42].
Perforated patch-clamp electrophysiology. KV7 currents were recorded using the
amphotericin-B perforated patch-clamp technique in voltage-clamp mode. At a holding
potential of -10 mV (corrected for junction potential), KV7 currents were recorded by
applying 500 ms voltage steps at 10 mV intervals from voltages ranging -80 mV to +40
mV. To effectively isolate KV7 currents, recordings were made in the presence of the
selective large conductance voltage- and Ca2+-activated K+ (BK) channel inhibitor
paxilline (1 µM) and GdCl3 (50 µM), an inhibitor of non-selective cation channels and Ltype voltage-gated Ca2+ channels [17, 52]. The amphotericin-B perforated patch-clamp
technique in current-clamp mode (I=0) was used to record the DSM cell membrane
potential as previously described [7, 42].
In situ Proximity Ligation Assay (PLA). In situ PLA was performed on freshly-isolated
DSM cells using the Duolink® in Situ orange starter kit goat/rabbit (Cat. No: DUO92106,
Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions. DSM cells
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underwent fixation in 2% paraformaldehyde (10 min, 37°C) followed by two 15-min
washes in phosphate buffered saline. DSM cells were then blocked in Duolink blocking
solution (30 min, 37°C). Subsequently, DSM cells were incubated with the anti-rabbit
KV7.4 (Santa Cruz Biotechnology, Dallas, TX; Cat. No.: sc-50417) and anti-goat KV7.5
(Cat. No.: sc-18048) antibodies or with the control anti-goat inositol triphosphate receptor
(IP3R) antibody (Cat. No.: sc-28614), respectively, in Duolink antibody diluent solution
overnight at 4°C, followed by 2x5 min washes in Duolink 1x wash buffer A solution. DSM
cells were then incubated with the Duolink PLA probe anti-rabbit MINUS and anti-goat
PLUS oligonucleotide-conjugated secondary antibodies (1 h, 37°C), followed by 2x5 min
washes in Duolink 1x wash buffer A solution. DSM cells were then incubated in ligaseligation solution (30 min, 37°C), which hybridizes the two PLA MINUS and PLUS probes
when in close proximity (<40 nm). Following ligation, DSM cells were washed 2x2 min
in Duolink 1x wash buffer A solution. Finally, DSM cells were incubated in amplificationpolymerase solution (100 min, 37°C) containing nucleotides and fluorescently-labelled
oligonucleotides. The oligonucleotide arm of one PLA probe is a primer for rolling-circle
amplification (RCA). The fluorescently-labeled oligonucleotides hybridize to the RCA
product thus permitting detection. Following amplification, DSM cells were washed 2x10
min in 1x wash buffer B and then a 1 min wash in 0.01x wash buffer B. Slides were then
mounted using minimal volume of Duolink in situ mounting medium with 4',6-diamidino2-phenylindole, dihydrochloride (DAPI). PLA signals (Duolink In Situ Detection Reagents
Orange (λexcitation/emission=554/576 nm)) were detected using laser scanning LSM 700
confocal microscope (Carl Zeiss, Germany) with a 63x oil immersion objective.
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Solutions and drugs. Nominally Ca2+-free dissection solution contained the following (in
mM): 80 monosodium glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES); 2 MgCl2; NaOH was used to attain pH 7.3.
Ca2+-containing physiological saline solution contained the following (in mM): 119 NaCl;
4.7 KCl; 24 NaHCO3; 1.2 KH2PO4; 2.5 CaCl2; 1.2 MgSO4; 11 glucose; that was aerated
with 95% O2/5% CO2 to attain pH 7.4. Physiological bath solution utilized for patch-clamp
experiments was composed of the following (in mM): 134 NaCl; 6 KCl; 1 MgCl2; 2 CaCl2;
10 glucose; 10 HEPES; and NaOH was used to obtain pH 7.4. The patch-pipette solution
contained (in mM): 110 potassium aspartate; 30 KCl; 10 NaCl; 1 MgCl2; 10 HEPES; 0.05
ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA); NaOH was
used to adjust the pH to 7.2. Amphotericin-B stock solution was prepared daily in dimethyl
sulfoxide (DMSO) and was included in the pipette solution (200-300 μg/ml) before the
experiment and was replaced every 1-2 h. ML213, TTX citrate, and XE991 were purchased
from Tocris Bioscience (Minneapolis, MN). Fura-2 AM was purchased from Life
Technologies (Cat No.: F1221, Carlsbad, CA). ML213 and Fura-2 AM were dissolved in
DMSO, while XE991 and TTX citrate were dissolved in double-distilled water. All other
chemicals were obtained from Fisher Scientific (Waltham, MA), Sigma-Aldrich, or
Worthington Biochemical Corp. (Lakewood, NJ).
Data Analysis and Statistics. Isometric DSM tension recording experiments for
spontaneous phasic, pharmacologically-induced, and nerve-evoked contractions were
conducted and analyzed as previously described [7, 42, 51]. Perforated whole cell patchclamp experiments were performed and analyzed using pCLAMP 10.3. Where specified in
the summarized data, “n” represents the number of freshly-isolated DSM strips or cells,
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and “N” represents the number of guinea pigs. Statistical analyses were based on the
number of DSM cells or strips, respectively (i.e. “n”). For spontaneous contraction
experiments, statistical analysis for the comparison of ML213 in the absence or presence
of XE991, two-way ANOVA test was performed followed by Bonferroni post-hoc test.
Paired Student’s t-tests were used for the remaining statistical analyses. Summarized data
are reported as means±SEM. P values <0.05 were considered statistically significant. Corel
Draw Graphic Suite X3 software (Corel Co., Mountain View, CA) and GraphPad Prism
4.03 software (La Jolla, CA) was used for data illustration.
RESULTS
ML213 decreased spontaneous phasic contractions in DSM isolated strips. To explore
the physiological effects of KV7 channel pharmacological activation with ML213 on
spontaneous phasic contractions, we conducted isometric DSM tension recordings on DSM
isolated strips. ML213 (0.1-30 µM) caused a concentration-dependent inhibition of
spontaneous phasic contractions in DSM isolated strips (n=6, N=6; P<0.05; Fig. 4.1).
Pretreatment of DSM isolated strips with the K V7 channel inhibitor XE991 (10 µM)
abolished ML213 (0.1-30 µM)-induced inhibition of spontaneous phasic contractions,
confirming selectivity for KV7 channels (n=6 N=6; P<0.05; Fig. 4.1). IC50 and maximal
efficacy values for ML213 on spontaneous phasic contractions are reported in Table 4.1.
ML213 decreased KCl-induced contractions in DSM isolated strips. Next, we
elucidated the effects of ML213 (0.1-30 µM) on DSM contractions induced by mild
membrane depolarization using 20 mM KCl. In the presence of 20 mM KCl, ML213 (0.130 µM) caused a concentration-dependent inhibition of DSM contractions and exhibited a
decrease in potency in comparison to ML213 inhibitory effects on spontaneous phasic
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contractions (see Table 4.1) (n=7, N=7; P<0.05; Fig. 4.2). To further explore the role of
K+ conductance in ML213-induced inhibition of DSM contractions and the potential direct
interaction with L-type voltage-gated Ca2+ channels, we tested the effects of ML213 (10
μM) on tonic DSM contractions stimulated by high 60 mM KCl. Here, ML213 (10 μM)
decreased 60 mM KCl-induced muscle tone to only 74±3.5% of the control (n=8, N=4;
P<0.01; Fig. 4.4). Subsequent application of the L-type voltage-gated Ca2+ channel
inhibitor nifedipine, however, caused an inhibitory effect significantly greater in
comparison to ML213, decreasing DSM tone to 39.7±6.4% of the control (n=8, N=4;
P<0.001; Fig. 4.4). The difference between the inhibitory effects of ML213 (10 µM) and
nifedipine on tonic DSM contraction were statistically significant (n=8, N=4; P<0.001;
Fig. 4.4). These data suggest ML213 does not directly inhibit L-type voltage-gated Ca2+
channel activity in DSM.
Carbachol attenuated ML213-induced inhibition of DSM contractions in a
concentration-dependent manner. We next sought to determine the potential
involvement of muscarinic acetylcholine receptor (mAChR) signaling in ML213-induced
inhibition of DSM contractility. This was achieved by examining the inhibitory effects of
ML213 (0.1-30 µM) on DSM contractions stimulated by the mAChR agonist CCh (0.1 or
1 µM). ML213 (0.1-30 µM) caused a concentration-dependent inhibition of both 0.1 µM
and 1 µM CCh (n=6, N=6 for both; P<0.05; Fig. 4.3). However, in comparison to 0.1 µM,
mAChR stimulation with 1 µM CCh markedly reduced the potency of ML213 on DSM
contraction amplitude and muscle force (see Table 4.1). .IC50 and maximal efficacy values
for ML213 on 0.1 µM and 1 µM CCh-induced DSM contractions are reported in Table
4.1.
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Figure 4.1. KV7 channel pharmacological activation with ML213 leads to an
inhibition of spontaneous phasic contractions in DSM isolated strips. A) A
representative isometric DSM tension recording demonstrating that ML213 (0.1-30 µM)
inhibited spontaneous phasic contractions in a DSM isolated strip. B) A representative
isometric DSM tension recording illustrating the K V7 channel inhibitor XE991 (10 µM)
abolished the inhibitory effects of ML213 (0.1-30 µM) on DSM spontaneous phasic
contractions. C-F) Cumulative concentration-response curves for ML213 on DSM phasic
contraction: C) amplitude, D) muscle force, E) duration and F) frequency in the absence
and presence of the KV7 channel inhibitor XE991 (n=6, N=6; *P<0.05, **P<0.01, and
***P<0.001). #P<0.05, ##P<0.01, and ###P<0.001 indicate statistical significance in the
effects of ML213 on spontaneous phasic contractions in the absence (control) versus
presence of XE991 (n=6, N=6). See Table 4.1 for potency and maximum efficacy values.

50

Figure 4.2. KV7 channel pharmacological activation with ML213 leads to an
inhibition of 20 mM KCl-induced phasic contractions in DSM isolated strips. A) A
representative isometric DSM tension recording demonstrating the concentrationdependent inhibition of 20 mM KCl-induced DSM phasic contractions by ML213 (0.1-30
µM). B-E) Cumulative concentration-response curves for the inhibitory effects of ML213
on DSM phasic contraction: B) amplitude, C) muscle force, D) duration and E) frequency
(n=7, N=7; *P<0.05 and ***P<0.001). See Table 4.1 for potency and maximum efficacy
values.
ML213 decreased nerve-evoked contractions in DSM isolated strips. To further
explore potential roles for mAChRs in ML213-induced inhibition of DSM contractions,
ML213 (0.1-30 µM) inhibitory effects were examined on nerve-evoked contractions
stimulated by either 10 Hz or 20 Hz EFS. ML213 (0.1-30 µM) caused a concentrationdependent inhibition of EFS-induced contractions stimulated continuously at both 10 and
20 Hz EFS frequencies (n=7, N=6 for 10 Hz; n=6, N=6 for 20 Hz; Fig. 4.5).
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Figure 4.3. Differential inhibitory effects of ML213 and nifedipine on 60 mM KClinduced tonic contractions in DSM isolated strips. A) A representative isometric DSM
tension recording demonstrating the differential effects of 10 µM ML213 and 1 µM
nifedipine upon a depolarization-induced DSM tonic contraction caused by 60 mM KCl in
a DSM isolated strips. B) Summarized data demonstrating the differential inhibitory effects
of ML213 (10 µM) and nifedipine (1 µM) on DSM 60 mM KCl-induced tonic contraction
(n=8, N=4; ##P<0.01 vs. control, and **P<0.001 ML213 vs. nifedipine, respectively).
IC50 and maximal efficacy values for ML213 on 10 Hz and 20 Hz EFS-induced contractions
are reported in Table 4.1. In comparison to 10 Hz EFS, the potency of ML213 on 20 Hz
EFS-induced contractions was reduced by more than two-fold (see Table 4.1). Next,
ML213 (1 or 3 µM) inhibitory effects were examined on contractions induced over a range
of EFS frequencies (0.5-50 Hz). ML213 (1 or 3 µM) decreased the amplitude of 10-50 Hz
EFS-induced contractions (n=6, N=6; P<0.05; Fig. 4.6).
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ML213 decreased global intracellular Ca2+ concentrations in DSM isolated strips. We
next aimed to assess the effects of ML213 on global intracellular Ca2+ concentrations of
isolated DSM strips loaded with fura-2. This was achieved using the ratiometric
fluorescence Ca2+ indicator fura-2 AM and measuring the emission at 510 nm with
excitation at 340 and 380 nm. Under control conditions in the absence of ML213, the mean
intensity (F340/F380) was 0.84±0.05 (n=7, N=6) and in the presence of ML213 (10 µM) the
mean F340/F380 ratio was decreased to 0.77±0.05 (n=7, N=6; P<0.05; Fig. 4.7). These results
suggest KV7 channel pharmacological activation with ML213 critically regulates global
intracellular Ca2+ concentrations in DSM isolated strips and thus DSM contractility.
ML213 decreased global intracellular Ca2+ concentrations in DSM isolated strips. We
next aimed to assess the effects of ML213 on global intracellular Ca2+ concentrations of
isolated DSM strips loaded with fura-2. This was achieved using the ratiometric
fluorescence Ca2+ indicator fura-2 AM and measuring the emission at 510 nm with
excitation at 340 and 380 nm. Under control conditions in the absence of ML213, the mean
intensity (F340/F380) was 0.84±0.05 (n=7, N=6) and in the presence of ML213 (10 µM) the
mean F340/F380 ratio was decreased to 0.77±0.05 (n=7, N=6; P<0.05; Fig. 4.7). These results
suggest KV7 channel pharmacological activation with ML213 critically regulates global
intracellular Ca2+ concentrations in DSM isolated strips and thus DSM contractility.
ML213 enhanced the amplitude of whole cell KV7 currents in freshly-isolated DSM
cells. We next sought to examine the pharmacological effects of ML213 on whole cell KV7
currents using the perforated patch-clamp technique in voltage-clamp mode. In the first
series of experiments, KV7 currents were recorded at a holding potential of -10 mV wherein
500 ms voltage steps were applied at 10 mV intervals from -80 mV to +40 mV.
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Figure 4.4. KV7 channel pharmacological activation with ML213 leads to an
inhibition of CCh-induced DSM phasic contractions. A) A representative isometric
DSM tension recording demonstrating the concentration-dependent inhibition of 0.1 µM
CCh-induced phasic contractions in a DSM isolated strip. B) A representative isometric
DSM tension recording demonstrating the concentration-dependent inhibition of 1 µM
CCh-induced phasic contractions in a DSM isolated strip. C-F) Cumulative concentrationresponse curves for ML213 on CCh (0.1 or 1 µM)-induced DSM phasic contraction C)
amplitude and D) muscle force, E) duration, and F) frequency (n=6, N=6 for both data sets;
#
P<0.05, ###P<0.001). See Table 4.1 for potency and maximum efficacy values.
To effectively isolate KV7 currents, recordings were made in the presence of the selective
large-conductance voltage- and Ca2+- activated K+ (BK) channel inhibitor paxilline (1 µM)
and GdCl3 (50 µM), an inhibitor of non-selective cation and L-type voltage-gated Ca2+
channels.
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Figure 4.5. KV7 channel pharmacological activation with ML213 leads to an
inhibition of nerve-evoked contractions induced by 10 Hz and 20 Hz EFS in DSM
isolated strips. A) A representative isometric DSM tension recording demonstrating the
concentration-dependent inhibition of 10 Hz EFS-induced contractions by ML213 (0.1-30
µM) in DSM isolated strips. B) A representative isometric DSM tension recording
illustrating the concentration-dependent inhibition of 20 Hz EFS-induced contractions by
ML213 (0.1-30 µM) in DSM isolated strips. C-D) Cumulative concentration-response
curves for ML213 on DSM EFS-induced: C) contraction amplitude and D) muscle force
(n=7, N=6 for 10 Hz; n=6, N=6 for 20 Hz; *P<0.05 for 10 vs. 20 Hz). See Table 4.1 for
potency and maximum efficacy values.
Further, the more depolarized holding potential of -10 mV that we used ensures
inactivation of other non-KV7 K+ channels, such as inward-rectifying K+ channels [53].
ML213 (10 µM) caused a significant increase in the amplitude of whole cell K V7 currents
at all voltages from -50 to +40 mV (n=7, N=5; P<0.05; Fig. 4.8). We further sought to
examine the time course for the pharmacological effects of ML213 on KV7 currents in
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DSM cells. This was achieved using a one-step voltage-clamp protocol with a 5 s duration
stimulus applied every 20 s from a -10 mV holding potential to +40 mV. ML213 (10 µM)

Figure 4.6. ML213 decreases 0.5-50 Hz EFS-induced contractions in DSM isolated
strips. A-C) The original isometric DSM tension recordings of 0.5-50 Hz EFS-induced
contractions in DSM isolated strips A) before (control), and after the addition of B) 1 µM
ML213, and C) 3 µM ML213. D-E) Cumulative frequency-response curves demonstrating
the inhibitory effects of D) 1 µM ML213 and E) 3 µM ML213 on the amplitude of 0.5-50
Hz EFS-induced contractions in DSM isolated strips (n=6, N=6 for both data sets; *P<0.05,
**P<0.01, and ***P<0.001).
caused a significant increase in the whole cell KV7 current amplitude by 106.7±54.95%
and 48.4±21.33%, respectively, in comparison to the control (n=8, N=5, P<0.05; Fig. 4.9).
ML213 hyperpolarizes the resting membrane potential in freshly-isolated DSM cells.
Using the perforated whole cell patch-clamp technique in current-clamp mode, we next
sought to determine the physiological role of ML213-sensitive KV7 channels in regulating
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the DSM cell membrane potential. ML213-induced inhibitory effects were examined in 6
DSM isolated cells from 6 different animals, which had an average resting membrane
potential of -22±4.2 mV. ML213 hyperpolarized the DSM cell membrane potential from
the control value of -22±4.2 mV to -42.6±4.2 mV (n=6, N=6; P<0.05; Fig. 4.10). ML213induced DSM cell membrane hyperpolarization was fully reversible by washout of ML213
(Fig. 4.10). On the contrary, XE991 (10 µM) depolarized the DSM cell membrane potential
from -29.8±4.3 to -18.7±2.7 and blocked ML213 (10 µM) hyperpolarization at -20.6±2.8
(n=8, N=4; P<0.05; Fig. 4.10), confirming ML213 selectivity for the KV7 channels. XE991
(10 µM) was also effective in reversing the hyperpolarizing effects of ML213 from 39.2±9.2 to -23.2±5.5 (control was -26.6±7.2) (n=7, N=6; P<0.05; Fig. 4.11). These
combined results suggest key involvement for ML213-sensitive KV7.2, KV7.4, and KV7.5
channels in regulating the DSM cell membrane potential.
KV7.4 and KV7.5 channel α-subunits assemble to form heteromeric KV7.4/KV7.5
channel subtypes in freshly-isolated DSM cells. Using in situ PLA, we sought to
determine whether KV7.4 and KV7.5 channels, among the key targets of ML213, form
heteromeric channels in freshly-isolated DSM cells. In situ PLA demonstrated KV7.4 and
KV7.5 channel subunits associate to form heteromeric K V7.4/KV7.5 channels in isolated
DSM cells. As shown in Figure 4.12, in situ PLA experiments demonstrated the colocalization of KV7.4 and KV7.5, channel α-subunits within 40 nm and within the vicinity
of the DSM cell membrane. Primary antibodies against the IP3R, which would not be
expected to co-localize with members of the KV7 channel family, were used as a negative
control. Co-incubation of the KV7.4 channel primary antibody with the primary antibody
of the IP3Rs yielded no PLA fluorescent signal (Fig. 4.12). These combined results suggest
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that KV7.4 and KV7.5 channel subunits assemble to form heteromeric KV7.4/KV7.5 channel
subtypes in DSM cells.
DISCUSSION
The current study utilized the novel compound ML213, a potent and selective activator of
KV7.2, KV7.4, and KV7.5-containing channels, to elucidate their physiological roles in
DSM excitability and contractility. ML213 inhibited spontaneous, pharmacologicallyinduced, and nerve-evoked DSM contractions and decreased global intracellular Ca2+
concentrations in DSM strips. ML213 enhanced whole cell KV7 currents and
hyperpolarized the resting membrane potential of freshly-isolated DSM cells. In situ PLA
studies further revealed the expression of heteromeric K V7.4/KV7.5 channels within the
vicinity of the DSM cell membrane, which are key pharmacological targets of ML213.
Previous studies on guinea pig, including those from our group, have demonstrated a role
for KV7 channels in DSM function through the use of K V7 channel pharmacological
modulators [7, 8, 42]. ML213 promoted concentration-dependent inhibition of spontaneous
phasic contractions with IC50 values of 1.1 and 0.7 µM, respectively (Fig. 4.1 and Table
4.1). Consistently, the inhibitory effects of ML213 on DSM contractile activity in our study
are consistent with previous reports in human and pig DSM [9, 28, 44]. Based on our data,
ML213 displays greater potency in comparison to retigabine, the K V7.1 channel activator
L-364373, and the KV7.2/KV7.3 channel activator ICA-069673 for inhibiting DSM
spontaneous phasic contraction amplitude and muscle force [7, 8, 42]. ICA-069673 and
ML213 have each been demonstrated to potently activate homomeric K V7.4 channels,
however, the key distinction between these two compounds was the ability for ML213 to
potently activate homomeric KV7.5 and heteromeric KV7.4/KV7.5 channels [31].
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Figure 4.7. ML213 decreases global intracellular Ca2+ concentrations in DSM isolated
strips. A) Original recordings illustrating that ML213 (10 µM) significantly decreased
global intracellular Ca2+ levels in a fura 2-loaded DSM strip. B) Summarized data
representing the reduction in global Ca2+ levels by 10 µM ML213 in DSM isolated strips
(n=7, N=6; *P<0.05).
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Figure 4.8. ML213 (10 µM) enhanced whole cell KV7 currents in freshly-isolated DSM
cells. A) Representative whole cell patch-clamp recordings illustrating the potentiation of
KV7 currents induced by the introduction of ML213 in the bath external solution. Paxilline
(1 µM) and GdCl3 (50 µM) were present in the solution. B) Current-voltage relationships
obtained in the absence (control) or presence of 10 µM ML213 in a whole cell voltageclamp recording. The two curves represent the current–voltage relationship expressed as
normalized current in the absence or presence of 10 µM ML213 (n=7, N=5, *P<0.05). Top
left insert: 500 ms voltage-step protocol from -80 to +40 mV with holding potential at -10
mV.
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Figure 4.9. Time course of ML213-induced activation of KV7 channel currents in
freshly-isolated DSM cells. A) Effects of ML213 on KV7 currents recorded using a onestep voltage-clamp protocol with a 5 s duration stimulus applied every 20 s from a -10 mV
holding potential to +40 mV. B) Representative traces (and voltage step used) of the
experiment plotted in A) for the control, ML213 (10 µM) and washout of ML213. C)
Summary data for the percentage of KV7 currents in the presence of ML213 compared to
control at -10 and +40 mV respectively (n=8, N=5, *P<0.05). Summarized data illustrate
the average of 4 to 6 points of each steady-state current.
The greater capacity and potency for ML213 to inhibit spontaneous phasic,
pharmacologically-induced, and EFS-induced DSM contractions (Figs. 4.1-4.6) in
comparison to ICA-069673 [42], potentially implicates key involvement of K V7.4 or
KV7.5-containing channels in DSM function. Similar observations were reported by studies
using ML213 in rodent mesenteric arteries, where the K V7.4 channels subtypes are
predominately expressed [23]
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Figure 4.10. ML213 hyperpolarizes the resting membrane potential in freshlyisolated DSM cells. A) A representative membrane potential recording in current-clamp
mode illustrating that ML213 (10 µM) hyperpolarized the DSM cell membrane potential
in a freshly-isolated DSM cell and that this effect was reversible by washout. B)
Summarized data for the hyperpolarizing effects of ML213 (10 µM) on the DSM cell
membrane potential (n=6, N=6; *P<0.05). C) A representative membrane potential
recording in current-clamp mode demonstrating that XE991 (10 µM) depolarized the DSM
cell membrane potential and blocked ML213 (10 µM) hyperpolarization in a freshlyisolated DSM cell (D) Summarized data for XE991 (10 µM)-induced depolarization in
freshly-isolated DSM cells and the lack of ML213 (10 µM) hyperpolarizing effects in the
presence of 10 µM XE991 (n=8, N=4; *P<0.05).
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Figure 4.11. ML213-induced hyperpolarization is reversed by KV7 channel inhibition
with XE991. A) A representative current-clamp recording from a freshly-isolated DSM
cell illustrating hyperpolarization of the DSM cell membrane potential by ML213 (10 µM)
and that the ML213-induced hyperpolarization is reversed by the K V7 channel inhibitor
XE991 (10 µM). B) Summary data for the hyperpolarizing effects of ML213 (10 µM) on
the DSM cell membrane potential (n=7, N=5, *P<0.05, effects reversible by 10 µM XE991
(n=7, N=5, #P<0.05). NS-non-significant.
The ability of ML213 to inhibit DSM contractions was decreased in a
concentration-dependent manner by the mAChR agonist CCh (Fig. 4.4). Consistently,
ML213 exhibited a reduced potency on 20 Hz EFS-induced DSM contractions in
comparison to 10 Hz (Fig. 4.5). ML213 inhibitory effects on CCh and EFS-induced DSM
contractions are consistent with previous reports in pigs and humans [9, 28]. These results
suggest that cellular pathways leading to the activation K V7 channels may potentially
function in opposition to mAChR signaling. However, confirming the existence of
functional link between KV7 channels and mAChRs in DSM will require additional future
studies involving extensive pharmacological and electrophysiological approaches.
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Parasympathetic nerves release ACh and ATP which act on mAChRs and purinergic
receptors, respectively, to trigger bladder contraction during micturition [1, 2, 54]. AChinduced activation of mAChRs constitutes the primary mechanism initiating bladder
contractions during micturition [1]. EFS evokes ACh release from parasympathetic nerve
terminals, which leads to depolarization of the DSM cell membrane potential and
associated DSM contractions [3]. While mAChR regulation of KV7 channel activity is
consistent with early studies in neurons [45], whether a similar regulatory mechanism
exists in DSM remains unknown. A recent study in airway smooth muscle reported that,
unlike neuronal KV7 channels [55], mAChR activation by CCh did not exhibit significant
inhibitory effects on KV7 currents [41]. Thus, KV7 channel activation in DSM may act in
opposition to mAChRs through an indirect mechanism, for example, activation of L-type
voltage-gated Ca2+ channels. Nonetheless, regulation of KV7 channels by mAChRs in DSM
represents an interesting topic for future investigations. Consistent with ML213 inhibitory
effects on DSM contractions, we further observed attenuation of global intracellular Ca 2+
concentrations by ML213 in DSM strips (Fig. 4.7).
For the first time, we report the activation of whole cell KV7 currents by ML213 in
freshly-isolated DSM cells (Figs. 4.8-9). The use of a more depolarized holding potential
(-10 mV) in our study ensures inactivation of other non-KV7 K+ channels, such as inwardrectifying K+ channels [53]. Also, at -10 mV holding potential, some of the KV7 channels
are open and generate quantifiable currents, which are not contaminated by the presence of
non-selective cation currents due to the inclusion of GdCl3. Thus, the stimulatory effects
of ML213 on KV7 currents are evident (Fig. 4.8). Our data support the concept that the
hyperpolarizing currents following addition of ML213 are a direct result of K V7 channel
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pharmacological activation. In a series of experiments, we used short voltage steps (500
ms) marginally revealing the kinetics of voltage-dependence of activation of the K V7
channels. Alternatively, using longer voltage-step protocols (5 s) with multiple voltage
steps may result in time-dependent rundown after several minutes of recording. Hence, we
sought to examine the time course effects of ML213 on KV7 current activity by performing
a one-step 5 s voltage-clamp protocol from a -10 mV holding potential to +40 mV at 20 s
intervals (Fig. 4.9). This protocol allowed for the recording of KV7 channel currents
without encountering substantial current run-down. The stimulatory effects of ML213 on
KV7 currents were modest, but statistically significant (Fig. 4.8). Albeit, it is wellestablished that small changes in DSM cell excitability can have pronounced effects on
DSM contractility [56, 57]. Indeed, we observed very robust ML213 inhibitory effects on
DSM contractility (Figs. 4.1-4.3).
Overall, the experimental design for our electrophysiological experiments aimed
not only to examine KV7 current activity and its response to pharmacological activation
with ML213, but also to mimic a physiological environment characterized by a more
depolarized resting membrane potential, which normally occurs under physiological
conditions during the action potential. Activation of ML213-sensitive KV7 channels was
further shown to hyperpolarize the DSM cell membrane potential (Fig. 4.10), consistent
with ML213 inhibitory effects on global intracellular Ca2+ concentrations and DSM
contractility. KV7 channel α-subunits are known to form functional homo- and heteromeric
channel conformations in vitro and in vivo [14, 40], with KV7.4, and KV7.5 being prominent
in smooth muscle tissues [58].
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In vascular myocytes, ML213 has been shown to activate heteromeric KV7.4/KV7.5
channels in addition to the homomeric channels composed either K V7.4 or KV7.5 channel
α-subunits, respectively [31, 49]. In addition to KV7.2 channel expression in guinea pig
DSM [7, 8, 42], KV7.4 [8], and KV7.5 [7, 8] channel α-subunits have been identified.
However, whether these KV7 channel subunits, in particular KV7.4 or KV7.5, associate to
form functional heteromers in DSM remains unknown. We confirmed the expression of
heteromeric KV7.4/KV7.5 channels in isolated DSM cells using in situ PLA. PLA
fluorescent signals for KV7.4/KV7.5 α-subunit co-localization were uniformly detected
through the DSM cell periphery, suggesting plasmalemmal expression of heteromeric
KV7.4/KV7.5 channels (Fig. 4.12). These findings, which are consistent with studies on
rodent vasculature [18] and provide strong evidence confirming heteromeric K V7.4/KV7.5
channel expression in DSM cells. While heteromeric K V7.4/KV7.5 channels are potently
activated by ML213 pharmacological activation, it has not yet been reported whether
heteromeric KV7.2/KV7.3 channels or other KV7.2-containing channels, are ML213sensitive. Albeit, the potential activation of KV7.2/KV7.3 channels, for example, by ML213
would presumably be mediated by the KV7.2 channel subunit as KV7.3 channel subtypes
are insensitive to ML213.
In addition, further studies to elucidate the precise stoichiometry of K V7 channels
and their associations with β-regulatory subunits (KCNE1-5) will be required to further
understand the potential ML213 targets in DSM. Indeed, a recent study in rodent arterial
myocytes demonstrated KCNE4 co-localization with KV7.4 and KV7.5 channels,
respectively [59]. Also, co-expression of KCNE4 with KV7.4 channels was found to
increase KV7.4 channel expression and current amplitudes [59]. Moreover, a report from
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bovine DSM suggests KV7.4 channel subtypes as the most abundantly expressed; findings
consistent with emerging studies in humans demonstrating K V7.4 mRNA expression as the
primary KV7 channel expressed in DSM [9, 60]. A separate group reported KV7.5 channel
mRNA expression as the most highly expressed KV7 channel subtype in human DSM [61].
Although ML213 and ICA-069673 activate KV7.2 channels, their differential selectivity
among KV7.4 and KV7.5-containing channels demonstrates the capacity for subtypespecific pharmacological targeting.
As our in situ PLA experiments provided decisive evidence confirming the
expression of heteromeric KV7.4/KV7.5 channel subtypes in DSM (Fig. 4.12), these
channels may be among the key pharmacological targets for ML213. Albeit, homomeric
KV7.4 and KV7.5 channel subtypes may also be critically involved as a previous report
revealed ML213 as equally potent among K V7.4 and KV7.5-containing channels [31].
Based on our novel findings regarding KV7 channel conformations in DSM in conjunction
with our recent electrophysiological studies of ML213, our data suggests key roles for
KV7.4- and KV7.5-containing channels, including KV7.4/KV7.5 heteromers, in mediating
the effects of ML213 in DSM. The ability to fine-tune KV7 channel pharmacological
modulators to exhibit improved selectivity between K V7.4, KV7.5, and KV7.4/KV7.5
channels, may represent a substantial breakthrough in the development of novel and
efficacious therapeutic modalities for lower urinary tract dysfunction.
In conclusion, our study demonstrates that ML213-sensitive KV7.4-and KV7.5containing channels are essential regulators of DSM excitability and contractility. KV7
channel activation by the novel activator ML213 leads to the activation of K V7 currents,
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hyperpolarization of the membrane potential, a decrease in global intracellular Ca2+
concentration, and the attenuation of DSM contractility.

Figure 4.12. PLA shows that KV7.4/KV7.5 heteromeric channels are expressed in
isolated guinea pig DSM cells. Images of a freshly-isolated DSM cell stained with the
combination of anti-KV7.4 and anti-KV7.5 channel antibodies (upper panels). PLA
fluorescent signals are shown in red. No PLA fluorescent signals were observed when the
anti-KV7.4 antibody was co-incubated with the anti-IP3R antibody (lower panels). An
orthogonal cross-section image of the DSM cell displaying PLA signals was obtained
following z-stack scans collected along the viewing plane indicated by the dashed (- - -)
lines and is represented directly below the top right panel. BF, bright field; DAPI, 4′,6Diamidine-2′-phenylindole dihydrochloride (nuclear staining shown in blue).
Table 4.1. IC50 and maximal efficacy values for the effects of ML213 DSM
Contractions
CONDITION
Spontaneous Phasic Contractions
KCl (20 mM)-Induced Contractions
CCh (0.1 µM)-Induced Contractions
CCh (1 µM)-Induced Contractions
10-Hz EFS-Induced Contractions
20-Hz EFS-Induced Contractions

AMPLITUDE
MUSCLE FORCE
DURATION
FREQUENCY
1.1 (0.5-2.4) µM;
0.7 (0.2-2.8) µM;
1.6 (0.8-2.9) µM; 3.9 (0.8-20.3) µM;
95.6 ± 4.4%
96.8 ± 3.2%
91.6 ± 8.41%
85.4 ± 14.6%
2.7 (1.4-5.1) µM;
2.5 (1.2-5.3) µM;
3.9 (1.9-8.2) µM;
n/a; 87.6 ± 8.2%
99.2 ± 0.8%
99.1 ± 0.9%
90.3 ± 9.7%
3.5 (1.9-6.4) µM;
2.1 (1.1-3.9) µM;
3.0 (1.8-5.3) µM;
n/a; 100% inhibition
100% inhibition
100% inhibition
99.7 ± 0.29%
6.2 (1.2-30.7) µM;
n/a; 92.1 ± 4.2%
n/a; 68 ± 9.5%
n/a; 47.1 ± 15.4%
84 ± 9.1%
2.2 (1.3-3.7) µM;
2.3 (1.3-4.1) µM;
n/a; 32.78 ± 13.5%
n/a
83.6 ± 7.6%
83.9 ± 8.2%
5.1 (3.1-8.2) µM;
4.7 (2.7-8.1) µM;
n/a; 37.46 ± 9.3%
n/a
86.9 ± 6.4%
89.1 ± 6.0%
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n/N
6/6
7/7
6/6
6/6
7/6
6/6

CHAPTER 5
PHYSIOLOGICAL ROLES OF VOLTAGE-GATED KV7.4/KV7.5 CHANNELS IN
HUMAN DETRUSOR SMOOTH M USCLE EXCITABILITY AND CONTRACTILITY
ABSTRACT
Emerging research efforts have established voltage-gated KV7 channels (KV7.1KV7.5) as key regulators of detrusor smooth muscle (DSM) function; however, essential
information regarding KV7 channel expression, tetrameric conformations, and
physiological roles remain to be explored at cellular and tissue levels in human DSM. We
used RT-PCR, , Western blot, immunocytochemistry, in situ proximity ligation assays
(PLA), ratiometric fluorescence Ca2+ imaging, isometric DSM tension recordings, and
perforated patch-clamp electrophysiology using freshly-isolated human DSM strips and
cells. Human DSM tissues were collected from ## donors undergoing routine open bladder
surgeries. RT-PCR detected mRNA transcripts for KV7 channel subtypes in human DSM
tissue and isolated cells. Western blot analysis and immunocytochemistry further
demonstrated KV7 channel protein expression in DSM tissue and isolated cells,
respectively. In situ PLA experiments identified co-localization of KV7.4 and KV7.5
channel subunits, suggesting expression of heteromeric K V7.4/KV7.5 channel subtypes in
human DSM cells. The KV7 channel activator, retigabine, decreased global Ca2+
concentrations in DSM isolated strips, while the K V7 channel inhibitor XE991 increased
global Ca2+ concentrations. Retigabine decreased spontaneous phasic and nerve-evoked
contractions in DSM isolated strips, while the K V7 channel inhibitor XE991 increased
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spontaneous phasic and nerve-evoked contractions in DSM isolated strips. Retigabineinduced DSM relaxation was attenuated in the presence of XE991. The K V7.2/KV7.3
channel activator ICA-069673 and KV7.1 activator L-364,373 also inhibited spontaneous
phasic contractions. In voltage-clamp mode of the perforated patch-clamp technique,
retigabine (10 µM) caused a significant increase in the amplitude of whole cell K V7
currents, effects reversible by washout or blocked by XE991. Further, retigabine
hyperpolarized the DSM resting membrane potential, while XE991 caused DSM
membrane depolarization. This study reveals novel aspects of KV7 channel function and
molecular composition in human DSM cells and tissues, strongly supporting their potential
therapeutic utility for treatment of lower urinary tract dysfunction.
INTRODUCTION
DSM contraction and relaxation underlies the two main functions of the urinary
bladder: the storage and release of urine. The excitability of DSM is critically regulated by
the activity of ion channels, including voltage-gated KV7 channels (KV7.1-KV7.5) [4]. KV7
channels have a prominent role in regulating the DSM resting membrane potential.
In contrast to other K+ channels, such as the large-conductance voltage- and Ca2+-activated
K+ channels, KV7 channels do not have a significant role in the repolarization phase of
action potentials [47, 57]. As the KV7 channels activate at membrane voltages near -60
mV, below the threshold for L-type voltage-gated Ca2+ channel activation, these channels
are critically involved in establishing the resting membrane potential [4, 62].
KV7 channels attain vast heterogeneity as their five pore-forming α-subunits form
distinct homo- or hetero-tetrameric complexes [14, 63]. Further, KV7 channels associate
with KCNE-encoded β-regulatory subunits (KCNE1-KCNE5), which may alter KV7
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channel biophysical properties including subcellular localization, pharmacology, and
selectivity [14-16, 40, 64]. In neurons, KV7 channel currents were initially characterized as
“M-currents” [65], preceding the determination that K V7.2/KV7.3 channels were the
molecular correlate of this current [66]. Also, early studies in the heart revealed the key
role of the KV7.1/KCNE1 channels in the cardiac delayed rectifier K + (IKs) current [46].
Nonetheless, based on the emergence of commercially available KV7 channel
pharmacological modulators, physiological roles for K V7 channels in other tissues,
including smooth muscle, is becoming apparent [14, 21, 40, 64, 67-69].
In DSM, KV7 channel functional roles, including in studies from our laboratory [7,
42], have recently been identified in the guinea pig [7, 8, 42], pig [28]; and rat (Rode, 2010,
20385123), where the KV7 channel activator retigabine was shown to have pronounced
effects in reducing DSM contractility [34]. This may elude to the increased micturition
volume and voiding intervals observed in rats subjected to acute retigabine exposure in
vivo [26, 28, 34]. More relevant, clinical evidence has proven retigabine to be associated
with the increased occurrence of urinary retention [70]. As the mechanism of action of
retigabine is via the activation of KV7 channels, its collateral side effect of urinary retention
is a significant observation that should be explored scientifically and in the context of
overall urinary bladder function and OAB medicinal treatment.
As important functional roles for KV7 channels in DSM function has been
established in experimental animals, it is of key interest to ascertain the translation
implications of these findings to humans. Indeed, the clinical effects of retigabine on
urinary bladder function are noteworthy, albeit evidence of K V7 channel expression and
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function in human DSM remains largely unexplored as documented by two similar tissuelevel studies in human DSM [9, 44].
In this study, we used RT-PCR, qPCR, Western blot, immunocytochemistry, and
in situ proximity ligation assays (PLA) to determine the mRNA and protein expression of
KV7 channels and the identify of which K V7 channel α-subunits assemble to form
functional tetramers. Further, we conducted ratiometric fluorescence Ca2+ imaging,
isometric DSM tension recordings, and perforated patch-clamp electrophysiology in
combination with KV7 channel pharmacological modulators to elucidate their
physiological role in regulating human DSM excitability and contractility. This study
provides the first molecular, cellular, and tissue-based examination of KV7 channel
expression and function in human DSM, where these channels serve a key role in overall
urinary bladder function.
MATERIALS AND METHODS
Ethical Approval. All procedures involving the acquisition of human DSM tissues for the
current studies have been reviewed and approved by the Institutional Review Board of the
Medical University of South Carolina (protocol number Pro00045232).
DSM cell isolation and collection. Human DSM single cells were freshly isolated using a
combination of papain and collagenase as previously described [32]. Human DSM cells
were used for electrophysiological experiments, PCR, or in situ PLA within 12 h after
isolation. Intact human DSM strips with urothelium removed were used for single cell
isolation, isometric DSM tension recordings, and ratiometric fluorescence Ca2+ imaging.
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RT-PCR
RT-PCR experiments were conducted on freshly-isolated human DSM tissues and cells as
previously described [32].
Western blot and Immunocytochemistry
Western blot and immunocytochemical experiments on human DSM tissues and freshlyisolated cells, respectively, were conducted as previously described [32].
In situ Proximity Ligation Assay. In Situ PLA was performed on freshly-isolated human
DSM cells using the Duolink In Situ Proximity Ligation Assay kit (Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. DSM cells
underwent fixation in 2% paraformaldehyde (10 min, 37°C) followed by two 15-min
washes in PBS. DSM cells were then blocked in Duolink blocking solution (30 min, 37°C).
Subsequently, isolated DSM cells were incubated with anti-rabbit KV7.#/anti-goat KV7.#
antibodies or anti-goat KV7.#/anti-rabbit KV7.# antibodies, respectively, in Duolink
antibody diluent solution overnight at 4°C, followed by 2 x 5 min washes in Duolink 1x
Wash Buffer A solution. DSM cells were then incubated with the Duolink PLA probe antirabbit MINUS and anti-goat PLUS oligonucleotide-conjugated secondary antibodies (1 h,
37°C), followed by 2 x 5 min washes in Duolink 1x wash buffer A solution. DSM cells
were then incubated in ligase-ligation solution (30 min, 37°C), which hybridizes the two
PLA MINUS and PLUS probes when in close proximity (<40 nm). Following ligation,
DSM cells were washed 2 x 2 min in Duolink 1x wash buffer A solution. Finally, DSM
cells were incubated in amplification-polymerase solution (100 min, 37°C) containing
nucleotides and fluorescently-labelled oligonucleotides. The oligonucleotide arm of one
PLA probe is a primer for rolling-circle amplification. The fluorescently-labeled
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oligonucleotides hybridize to the rolling-circle amplification product thus permitting
detection. Following amplification, DSM cells were washed 2 x 10 min in 1x wash buffer
B and then a 1 min wash in 0.01x wash buffer B. Slides were then mounted using minimal
volume of Duolink In Situ mounting medium with 4',6-Diamidino-2-Phenylindole,
Dihydrochloride (DAPI). PLA signals (Duolink In Situ Detection Reagents Orange
(λexcitation/emission= 554/576 nm)) were detected using a laser scanning LSM 700 confocal
microscope (Carl Zeiss, Germany) with a 63x oil immersion objective.
Isometric DSM tension recordings. Isometric DSM tension recordings were conducted
as previously described on isolated DSM strips void of urothelium [51]. For experiments
on spontaneous phasic contractions, the isolated DSM isolated strips were pretreated
tetrodotoxin (TTX, 1 µM), a neuronal voltage-gated Na+ channel blocker, before the
application of KV7 channel pharmacological modulators. Electric field stimulation (EFS)induced DSM contractions were stimulated with a PHM-152I programmable stimulator
(Med Associates, Inc., Georgia, VT, USA) in the absence of TTX. 0.5-50 Hz EFS-induced
contractions were stimulated at 3 min intervals over a wide range of frequencies (0.5, 2.0,
3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz) in the absence (control) and then in the presence
of either retigabine (10 µM) or XE991 (10 µM).
Ratiometric Fluorescence Ca2+ imaging. Global intracellular Ca2+ concentrations of
isolated human DSM strips were measured using the ratiometric fluorescence Ca 2+ probe
fura-2 AM as previously described [32].
Solutions and drugs. Ca2+-free dissection solution contained the following (in mM): 80
monosodium glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 4-(2-hydroxyethyl) piperazine-1ethanesulfonic acid (HEPES); 2 MgCl2; NaOH was used to attain pH 7.3. Ca2+-containing
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physiological saline solution contained the following (in mM): 119 NaCl; 4.7 KCl; 24
NaHCO3; 1.2 KH2PO4; 2.5 CaCl2; 1.2 MgSO4; 11 glucose; that was aerated with 95%
O2/5% CO2 to attain pH 7.4. Physiological bath solution utilized for patch-clamp
experiments was composed of the following (in mM): 134 NaCl; 6 KCl; 1 MgCl2; 2 CaCl2;
10 glucose; 10 HEPES; and NaOH was used to obtain pH 7.4. The patch-pipette solution
contained (in mM): 110 potassium aspartate; 30 KCl; 10 NaCl; 1 MgCl2; 10 HEPES; 0.05
ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA); NaOH was
used to adjust the pH to 7.2. Amphotericin-B stock solution was prepared daily in dimethyl
sulfoxide (DMSO) and was included in the pipette solution (200-300 μg/ml) before the
experiment and was replaced every 1-2 h. ML213, TTX citrate, and XE991 were purchased
from Tocris Bioscience (Minneapolis, MN). Fura-2 AM was purchased from Life
Technologies (Cat No.: F1221, Carlsbad, CA). ML213 and Fura-2 AM were dissolved in
DMSO, while XE991 and TTX citrate were dissolved in double-distilled water. All other
chemicals were obtained from Fisher Scientific (Waltham, MA), Sigma-Aldrich, or
Worthington Biochemical Corp. (Lakewood, NJ).
RESULTS
KV7 channel subtypes are expressed at the mRNA level in freshly-isolated human
DSM cells and tissues. To elucidate KV7 channel mRNA expression in human DSM, we
began by conducting conventional RT-PCR using human DSM tissues. At the tissue-level
in human DSM, we detected mRNA transcripts for all K V7 channel subtypes except KV7.2
(Figure 5.1). KV7 channels are known to be expressed in non-DSM tissues including
neurons and instersitial cells. Therefore, we sought to clarify K V7 channel mRNA
expression by conducting parallel RT-PCR experiments using RNA isolated specifically
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from human DSM single cells. At the cellular level in DSM, we identified transcripts for
KV7.4 and KV7.5 subunits.
KV7 channel subtypes are expressed at the protein-level in human DSM tissues and
freshly-isolated cells. To confirm KV7 channel protein expression in human DSM tissues
and freshly-isolated cells, we utilized Western blot analysis and immunocytochemistry
with confocal microscopy. As shown in Figure 5.2, Western blot data identified protein
expression for all KV7 channel subtypes except KV7.2 in human DSM tissue.
Chemiluminescent bands were not observed when K V7.1 and KV7.3-KV7.5 channel
antibodies were incubated in the presence of their competing peptides (+CP), respectively.
Again, as KV7 channels are expressed in non-DSM tissues within the detrusor layer, we
sought to confirm KV7 channel protein expression directly in freshly-isolated DSM cells
using immunocytochemistry with confocal microscopy (Figure 5.3).
KV7.4 and KV7.5 channel α-subunits associate to form heterotetrameric KV7.4/KV7.5
channel subtypes in freshly-isolated DSM cells. KV7 channel subunits (KV7.1-KV7.5)
differentially associate to form functional tetrameric channels with distinct biophysical
properties [14]. Using in situ PLA, we sought to determine whether K V7.4 and KV7.5
channels, the KV7 channel subtypes expressed in isolated DSM cells (Figure 1), form
heteromeric channels in freshly-isolated DSM cells. In situ PLA demonstrated KV7.4 and
KV7.5 channel subunits associate to form heteromeric K V7.4/KV7.5 channels in isolated
human DSM cells. As shown in Figure 5.4, in situ PLA experiments demonstrated the colocalization of KV7.4 and KV7.5, channel α-subunits within 40 nm and within the vicinity
of the DSM cell membrane. Primary antibodies against the IP3R, which would not be
expected to co-localize with members of the KV7 channel family, were used as a negative
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Figure 5.1. KV7 channels mRNA transcripts are present in freshly-isolated human
DSM cells and tissues. KV7 channel subtype mRNA detection in human DSM whole
tissues and freshly-isolated single cells. RT-PCR experiments detected mRNA for all KV7
channel subtypes except KV7.2 in whole human DSM tissues. Further experiments using
freshly-isolated human DSM single cells revealed K V7.4 and KV7.5 channels are the only
subtypes present at the mRNA level in human DSM. No bands were observed in the
absence of reverse transcriptase (-RT). Results were confirmed in experiments from at least
three DSM tissues isolated from 3 different patients.

Figure 5.2. Western blot analyses demonstrated protein expression for KV7.1 and
KV7.4-KV7.5 channel subtypes in human DSM. Western blot experiments demonstrate
protein expression for KV7.1-5 channel subtypes in human DSM. A) KV7.1, B) no KV7.2,
C) KV7.3, D) KV7.4 and E) KV7.5 channel subtypes were detected using K V7 channel
subtype-specific antibodies. Incubation of the KV7 channel primary antibodies with each
respective competing peptide (+CP) eliminated protein detection thereby confirming
antibody selectivity. These results were verified in at least three human DSM tissues
isolated from 3 different patients.
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Figure 5.3. KV7.1 and KV7.4-KV7.5 channel subtypes are expressed at the protein level
in freshly-isolated human DSM cells. Confocal images from immunocytochemical
experiments demonstrate the expression K V7.1- KV7.5 (A-E) channel subunits in freshlyisolated human DSM cells. Red staining indicates detection of KV7.1- KV7.5 channel
subunits, respectively. Blue staining indicates the nucleus. The anti-actin, α-smooth muscle
probe is shown in green (top right). The overlaid images for K V7.1- KV7.5 channels with
anti-actin, α-smooth muscle probe and DAPI nuclear stain is shown at the bottom right,
respectively. Co-localization of each KV7channel subtypes with the anti-actin, α-smooth
muscle is indicated by the yellow color in the merged images, respectively. Data were
confirmed in multiple experiments using DSM tissues from at least 3 guinea pigs. Images
were acquired with a Zeiss LSM 700 confocal microscope using a 63X oil objective.
control. Co-incubation of the KV7.4 channel primary antibody with the primary antibody
of the IP3Rs yielded no PLA fluorescent signal (Fig. 5.4). These combined results suggest
that KV7.4 and KV7.5 channel subunits assemble to form heteromeric KV7.4/KV7.5 channel
subtypes in DSM cells.
KV7 channels regulate spontaneous phasic contractions in human DSM isolated
strips. To elucidate whether KV7 channel pharmacological modulation of the KV7 channels
corresponds to functional changes in human DSM contractility, we conducted isometric
tension recordings on human DSM isolated strips. As demonstrated by Fig. 5.5, KV7
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channel pharmacological activation with retigabine (10 µM) decreased spontaneous phasic
contractions in human DSM isolated strips from control (non-OAB) and OAB patients
(n=9, N=5 for Control non-OAB, Fig. 5.5; n=5, N=5 for OAB, Fig. 5.5; *P<0.05). There
was no statistically significant difference in the inhibitory effects of retigabine on
spontaneous phasic contraction parameters in control versus OAB patients. The K V7
channel inhibitor XE991 (10 uM) increased spontaneous phasic contractions of DSM
isolated strips (n=12, N=7; *P<0.05; Figure 5.6, A-B). In the presence of XE991 (10 uM),
retigabine had no significant inhibitory effects on spontaneous phasic contractions (n=5,
N=4; *P<0.05; Figure 5.6, C-D), confirming the selectivity of retigabine for the K V7
channel subtypes. There was a statistically significant difference between the inhibitory
effects of retigabine in the absence versus presence of XE991, confirming the selectivity
of retigabine for KV7 channel subtypes.
KV7 channels regulate nerve-evoked contractions in human DSM isolated strips. We
next aimed to elucidate the role of the KV7 channels in regulating nerve-evoked
contractions in human DSM isolated strips using electrical field stimulation (EFS)
contractions induced over a range of EFS frequencies (0.5-50 Hz) in combination with KV7
channel pharmacological modulators. Retigabine (10 µM) caused a significant decrease in
the amplitude of 0.5-50 Hz EFS-induced contractions (n=7, N=4; P<0.05; Figure 5.7, DE). KV7 channel inhibition with XE991 decreased 0.5-50 Hz EFS-induced contractions
(n=6, N=5; P<0.05; Figure 5.7, A-B). These results poise the KV7 channels as important
regulators of nerve-evoked contractions in human DSM isolated strips.
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OVERALL CONCLUSIONS
This study examined the expression and physiological roles of voltage-gated KV7 channels
in human DSM excitability and contractility. PCR experiments detected mRNA transcripts
for KV7.1 and KV7.3-KV7.5 channel subtypes in DSM tissue, with only K V7.4-KV7.5
channel subtypes at the cellular level in human DSM. Western blot analysis confirmed
KV7.1 and KV7.3-KV7.5 channel protein expression in human DSM tissues. However,
immunocytochemistry revealed only KV7.4 and KV7.5 channel subtype protein expression
was present in freshly-isolated human DSM cells. Further, using in situ PLA, we confirmed
the molecular interaction between KV7.4 and KV7.5 channel α-subunits, suggesting
heteromeric KV7.4/KV7.5 channel subtype expression at the cellular level in human DSM
cells. Retigabine decreased spontaneous and nerve-evoked contractions, decreased global
Ca2+ concentrations, hyperpolarized the DSM cell membrane potential, and enhanced
whole cell KV7 currents in DSM cells. XE991 increased spontaneous and nerve-evoked
DSM contractions, increased global Ca2+ concentrations, depolarized the DSM cell
membrane potential, and blocked retigabine-induced inhibition of DSM contractions.
KV7 channel expression and functional roles have been emerging in recent years in reports
on experimental animals. However, studies of KV7 channel expression and function in
human DSM are currently lacking and represented by only two superficial and tissue-level
studies in human DSM [9, 44]. One of these studies reported the detection of mRNA
transcripts for all KV7 channel subtypes except KV7.2 at the tissue level in human DSM
[9]. Consistently, a second report in human DSM utilizing qPCR reported K V7 channel
subtype expression in rank order: KV7.4>KV7.5>KV7.3>KV7.1, with minimal or no
detection of KV7.2 channel subtypes [44].

80

Figure 5.4. In situ PLA detection of KV7.4/KV7.5 heteromeric channels expressed in
isolated guinea pig DSM cells. Images of a freshly-isolated DSM cell stained with the
combination of anti-KV7.4 and anti-KV7.5 channel antibodies (upper panels). PLA
fluorescent signals are shown in red. No PLA fluorescent signals were observed when the
anti-KV7.4 antibody was co-incubated with the anti-IP3R antibody (lower panels). An
orthogonal cross-section image of the DSM cell displaying PLA signals was obtained
following z-stack scans collected along the viewing plane indicated by the dashed (- - -)
lines and is represented directly below the top right panel. BF, bright field; DAPI, 4′,6Diamidine-2′-phenylindole dihydrochloride (nuclear staining shown in blue).
Protein expression for KV7.1, KV7.4, and KV7.5 channel subtypes was further
reported using Western blot analysis [44]. However, these experiments by Bientinesi et al.,
which excluded KV7.3 channel subtypes, did not include appropriate positive or negative
controls [44], which raise questions as to the validity of the data. Minimal or no expression
of KV7.2 channel mRNA has also been reported in several non-DSM tissue types across
multiple species including the murine and rat airway [20, 71], rat mesenteric arteries [72],
human airway smooth muscle [17], and in human arteries [22].
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Figure 5.5. Retigabine, a KV7.2-KV7.5 channel subtype activator inhibited
spontaneous phasic contractions in human DSM control and OAB patients.
Retigabine, a KV7.2- KV7.5 channel subtype activator, inhibited spontaneous phasic
contractions in human DSM. A) An original isometric DSM tension recording
demonstrating the inhibition of spontaneous phasic contractions by retigabine (10 µM). B)
Summarized data for the inhibitory effects of retigabine (10 µM) on human DSM
contraction parameters including contraction amplitude, muscle force, tone, contraction
duration, and frequency (n=9, N=5; ***P<0.001 for each). C) An original isometric DSM
tension recording demonstrating the inhibition of spontaneous phasic contractions by
retigabine (10 µM) in an OAB patient. D) Summarized data for the inhibitory effects of
retigabine (10 µM) on human DSM contraction parameters in control versus OAB patients
(n=3, N=3).
Interestingly, the expression of KV7.4 and KV7.5 channel subtype is consistent with
emerging reports of KV7 channel expression in smooth muscle tissues [22, 40, 73].
Nonetheless, conflicting reports exist in the literature concerning which K V7 channel
subtype (i.e. KV7.4 or KV7.5) is most highly expressed in human DSM. The most recent of
these two reports indicated KV7.4 channels were most highly expressed, while a separate
group demonstrated KV7.5 channel mRNA as the most highly expressed K V7 channel
subtype in human DSM [61, 74].While KV7 channel mRNA expression has been emerging,
whether corresponding protein expression occurs has not been fully explored.
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Figure 5.6. XE991, a KV7.1-KV7.5 channel subtype inhibitor increased spontaneous
phasic contractions and blocked retigabine-induced relaxation in human DSM
isolated strips. XE991, a KV7.1-KV7.5 channel subtype inhibitor increased spontaneous
phasic contractions in human DSM. A) An original isometric DSM tension recording
demonstrating the augmented spontaneous phasic contractions induced by XE991 (10 µM).
B) Summarized data for the stimulatory effects of XE991 (10 µM) on human DSM
contraction parameters including contraction amplitude, muscle force, tone, contraction
duration, and frequency (n=12, N=7; *P<0.05 and **P<0.01). C) An original isometric
tension recording demonstrating the effect of retigabine (10 µM) upon human DSM
spontaneous phasic contractions subject to pretreatment with XE991 (10 µM). D)
Summarized data comparing the effects of retigabine (10 µM) in the absence or presence
of XE991 (10 µM) upon human DSM contraction parameters including contraction
amplitude, muscle force, tone, contraction duration, and frequency (n=5-9, N=4-5;
**P<0.01 and ***P<0.001).
Our current data reveals the expression of KV7.4 and KV7.5 channel subtypes at the
mRNA and protein levels (Figure 5.1-5.4). This could be very significant as this
demonstrates the potential pharmacological efficacy of future selective KV7.4/KV7.5
channel activators as effective treatments for OAB, while KV7.2/KV7.3 selective
modulators may prove better for the treatment of neurological conditions. Thus, this may
abolish the large number of adverse effects associated with current OAB treatments and
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Figure 5.7. Retigabine and XE991 attenuated EFS-induced contractions in human
DSM. Original isometric tension recording illustrating 3.5-50 Hz EFS-induced
contractions before (A) and after (B) the addition of retigabine (10 µM). C) Frequencyresponse curves illustrating the inhibitory effects of retigabine on the amplitude of 3.5-50
Hz EFS-induced contractions (n=7, N=4; *P<0.05, **P<0.01, ***P<0.001). D) Original
isometric tension recording illustrating 3.5-50 Hz EFS-induced contractions before and
after (E) the addition of XE991 (10 µM). F) Frequency-response curves illustrating the
inhibitory effects of retigabine on the amplitude of 3.5-50 Hz EFS-induced contractions
(n=7, N=4; *P<0.05, **P<0.01, ***P<0.001).
Table 5.1 Human KCNQ Primer Sequences for PCR
Table 5.1 Human KCNQ Primer Sequences for PCR
F: 5'-CTGTCTTTGCCATCTCCTTCT-3'
KCNQ1 (180 bp)
R: 5'-GCGTCACCTTGTCTTCTACTC-3'
F: 5'-GGCTTCCTTTGTCTCATCCT-3'
KCNQ2 (190 bp)
R: 5'-CTGGACTGCAGGCTCTTAAT-3'
F: 5'-TCGGGTTCGCCTTTCTAATC -3'
KCNQ3 (195 bp)
R: 5'-GTGCCCTTGGTTGGGTAATA-3'
F: 5'-CCACCCTGTCCCTATTCTTTG-3'
KCNQ4 (201 bp)
R: 5'-GAAGCACTGTCTGGGAGTTT-3'
F: 5'-GCACTCCTTGGCATTTCTTTC-3'
KCNQ5 (173 bp)
R: 5'-GAGGCTTGTCGGCTCTTAAT-3'
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therefore the beneficial implications of this research is incredibly relevant to public health,
clinical medicine, and most importantly, quality of life. Based on our data from in situ
PLA, we provide compelling evidence to confirm the expression of heteromeric
KV7.4/KV7.5 channel subtypes in human DSM cells (Fig. 12). Therefore, heteromeric
KV7.4/KV7.5 channel subtypes may be among the key KV7 channel subtypes involved in
the regulation of DSM function. Although, homomeric K V7.4 and/or KV7.5 channel
subtypes may also be important for DSM function. Our novel findings concerning the
cellular and tissue-level expression of the KV7 channel, in conjunction with our functional
studies of DSM excitability and contractility, our data suggests key physiological roles for
the KV7 channels in human DSM function, with K V7.4 and KV7.5-containing channels,
including heteromeric KV7.4/KV7.5 channels, as potentially the upmost of physiological
relevance.
Nonetheless, taken together with our previous studies in the guinea pig (Chapters
3-4), further studies in human DSM will be required using multiple KV7 channel compound
with improved selectivity to that of retigabine. Further, electrophysiological experiments
will also prove helpful in human DSM in order to confirm K V7 channel drug effects are
indeed a result of direct modulation of KV7 current activity. The ability to fine-tune KV7
channel pharmacological modulators to exhibit improved selectivity between K V7.4,
KV7.5, and KV7.4/KV7.5 channels, may represent a substantial breakthrough in the
development of novel and efficacious therapeutic modalities for lower urinary tract
dysfunction. These combined studies may help to provide a rationale for further studies in
this area of research.
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CHAPTER 6
8

REGULATION OF TRANSIENT RECEPTOR POTENTIAL MELASTATIN 4 CHANNEL
BY SARCOPLASMIC RETICULUM INOSITOL TRIPHOSPHATE RECEPTORS: ROLE
IN HUMAN DETRUSOR SMOOTH MUSCLE FUNCTION

ABSTRACT
We recently reported key physiological roles for Ca2+-activated transient receptor potential
melastatin 4 (TRPM4) channels in detrusor smooth muscle (DSM). However, the Ca 2+signaling mechanisms governing TRPM4 channel activity in human DSM cells are
unexplored. As the TRPM4 channels are activated by Ca2+, inositol 1,4,5-trisphosphate
receptor (IP3R)-mediated Ca2+ release from the sarcoplasmic reticulum represents a
potential Ca2+ source for TRPM4 channel activation. We used clinically-characterized
human DSM tissues to investigate the molecular and functional interactions of the IP3Rs
and TRPM4 channels. With in situ proximity ligation assay (PLA) and perforated patchclamp electrophysiology, we tested the hypothesis that TRPM4 channels are tightly
associated with the IP3Rs and are activated by IP3R-mediated Ca2+ release in human DSM.
With in situ PLA, we demonstrated co-localization of the TRPM4 channels and IP3Rs in
human DSM cells. As the TRPM4 channels and IP3Rs must be located within close
apposition to functionally interact, these findings support the concept of a potential Ca 2+mediated TRPM4-IP3R regulatory mechanism. To investigate IP3R regulation of TRPM4
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channel activity, we sought to determine the consequences of IP3R pharmacological
inhibition on TRPM4 channel-mediated transient inward cation currents (TICCs). In
freshly-isolated human DSM cells, blocking the IP3Rs with the selective IP3R inhibitor
xestospongin-C significantly decreased TICCs. The data suggest that IP3Rs have a key role
in mediating the Ca2+-dependent activation of TRPM4 channels in human DSM. The study
provides novel insight into the molecular and cellular mechanisms regulating TRPM4
channels by revealing that TRPM4 channels and IP3Rs are spatially and functionally
coupled in human DSM.
INTRODUCTION
The functions of the urinary bladder – the principle organ charged with the storage
and periodic release of urine – are mediated by the activity of detrusor smooth muscle
(DSM). In DSM cells, it is well-established that Ca2+ influx through L-type voltage-gated
Ca2+ channels underlies the depolarization phase of spontaneous action potentials whilst
the large-conductance voltage- and Ca2+-activated K+ (BK) channels, in addition to other
voltage-gated KV channels, work in opposition to L-type voltage-gated Ca2+ channel
activity to promote membrane hyperpolarization[4, 57, 76, 77]. Albeit these mechanisms
have been known for many years in DSM, recent studies from our group have identified
an important role for an additional Ca2+-sensitive cationic conductance regulating DSM
function in rodents and humans[33, 78-80]. Indeed, Ca2+-activated monovalent cation
channels known as the transient receptor potential (TRP) melastatin 4 (TRPM4) channels
are functionally expressed in rat, guinea pig, and human DSM[33, 78-80].
Of the 28 members that constitute the TRP channel superfamily, TRPM4 channels,
in addition to TRPM5, are the only TRP channel members selective for monovalent cations
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(K+ and Na+)[81, 82]. TRPM4 channel functional roles in excitable cells and tissues,
including rodent[33, 79, 80] and human DSM[33, 78-80], have begun to emerge in recent
years following studies using the novel and selective TRMP4 channel inhibitor, 9phenanthrol[33, 79, 80, 83-85]. We recently provided the first detailed study demonstrating
the expression and key functional roles for TRPM4 channels in human DSM excitability
and contractility using the selective TRPM4 channel inhibitor 9-phenanthrol[78]. Our
novel study was the central topic of an editorial focus in the American Journal of
Physiology – Cell Physiology[86], which highlighted the attractiveness of the TRPM4
channels as potential novel targets for the pharmacological control of the urinary bladder.
Under pathophysiological conditions, DSM dysfunction is associated with some forms of
overactive bladder[12]. The TRPM4 channels, in addition to the cellular mechanisms
regulating their activity, represent an exciting and novel therapeutic approach to the
treatment of various bladder disorders and the collateral effects these conditions inflict on
patient quality of life. Nonetheless, significant work still remains to ascertain the cellular
mechanisms regulating TRPM4 channel activity in human DSM function to further
validate their potential therapeutic role for bladder disorders.
It has been suggested that Ca2+ release from the sarcoplasmic reticulum (SR)
inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs) may constitute a primary Ca2+ source
for TRPM4 channel activation[87]. The concept of IP3R-mediated Ca2+ release serving as
critically important Ca2+ source for TRPM4 channel activation, as opposed to Ca2+ influx
through L-type voltage-gated Ca2+ channels, was supported by the observation that
removal of extracellular Ca2+ had no acute effects on TRPM4 channel activity[87].
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Whether this TRPM4-IP3R regulatory mechanism exists in human DSM, however, is
completely unknown.
Therefore, the current study sought to investigate the molecular and functional
interaction of the TRPM4 channels and IP3Rs in human DSM. This was achieved via a
combined experimental approach using in situ proximity ligation assays (PLA) and
perforated patch-clamp electrophysiology in combination with pharmacological tools. This
study reveals the novel mechanism whereby SR IP3Rs regulate the excitability of human
DSM through molecular and functional interactions with TRPM4 channels.
MATERIALS AND METHODS
Human DSM tissue acquisition. Human DSM tissues were acquired from donor patients
undergoing routine open bladder surgeries as previously described[78, 88, 89]. All
procedures attendant upon the collection of human DSM tissues have been reviewed and
approved by the Institutional Review Board of the Medical University of South Carolina
(protocol number Pro00045232). 6 Caucasian patients (3 men and 3 women; average age
64.5±11.2 years) without preoperative histories of overactive bladder and American
Urological Association symptom scores <8 were used for this study. Following surgeries,
human DSM tissues were stored on ice in a container containing HEPES-buffered
dissection solution (see Solutions and Drugs) for immediate transport to the laboratory for
DSM cell isolation.
DSM cell isolation. Human DSM single cells were enzymatically isolated using a
combination of papain and collagenase as previously described[78, 88, 89]. Freshlyisolated DSM cells were used for in situ PLA or electrophysiological experiments within
12 h following isolation.
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In situ Proximity Ligation Assay (PLA). In situ PLA was performed on freshly-isolated
DSM cells using the Duolink® in situ orange starter kit goat/rabbit (Cat. No: DUO92106,
Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions. DSM cells
underwent fixation in 2% paraformaldehyde (10 min, 37°C) followed by two 15-min
washes in phosphate buffered saline. DSM cells were blocked in Duolink blocking solution
(30 min, 37°C). Subsequently, DSM cells were incubated with the anti-rabbit IP3R and
goat anti-TRPM4 channel antibodies (Santa Cruz Biotechnology, Dallas, TX; catalog
numbers SC-27540 TRPM4; SC-28614 IP3R), respectively, in Duolink antibody diluent
solution overnight at 4°C, followed by 2x5 min washes in Duolink 1x wash buffer A
solution. DSM cells were then incubated with the Duolink PLA probe anti-rabbit MINUS
and anti-goat PLUS oligonucleotide-conjugated secondary antibodies (1 h, 37°C),
followed by 2x5 min washes in Duolink 1x wash buffer A solution. DSM cells then
underwent incubation in ligase-ligation solution (30 min, 37°C), which hybridizes the two
PLA MINUS and PLUS probes when in close proximity (<40 nm). Following ligation,
DSM cells were washed 2x2-min in Duolink 1x wash buffer A solution. Finally, DSM cells
were incubated in amplification-polymerase solution (100 min, 37°C) containing
nucleotides and fluorescently-labelled oligonucleotides. The oligonucleotide arm of one
PLA probe is a primer for rolling-circle amplification. The fluorescently-labeled
oligonucleotides hybridize to the rolling-circle amplification product thus permitting
detection. Following amplification, DSM cells were washed 2x10 min in 1x wash buffer B
and then a 1 min wash in 0.01x wash buffer B. Slides were then mounted using minimal
volume of Duolink in situ mounting medium with 4',6-diamidino-2-phenylindole (DAPI).
PLA signals (Duolink In Situ Detection Reagents Orange (λexcitation/emission=554/576 nm))
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were detected using laser scanning LSM 700 confocal microscope (Carl Zeiss, Germany)
with a 63x oil immersion objective.
Patch-clamp electrophysiology. The amphotericin B-perforated whole cell patch-clamp
technique was used in all of the electrophysiological recordings as previously described[32,
33, 78, 80]. At the holding potential of -70 mV, the total open channel probability (NPo) of
TRPM4 channel-mediated transient inward cation currents (TICCs) before and after the
addition of xestospongin-C was analyzed. A stable recording period of at least 5-10 min
before and after the addition of xestospongin-C was utilized for analysis with pCLAMP
version 10.2 software (Molecular Devices, Union City, CA).
Solutions and drugs. The Ca2+-free dissection solution had the following composition (in
mM): 80 monosodium glutamate, 55 NaCl, 6 KCl, 2 MgCl2, 10 HEPES, and 10 glucose,
adjusted to pH 7.3 with NaOH. The extracellular (bath) solution used in the patch-clamp
experiments in the gap-free mode (both voltage- and current-clamp) contained (in mM):
134 NaCl, 6 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES, pH adjusted to 7.4 with
NaOH. The patch-clamp pipette solution for these experiments contained (in mM): 110
potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 10 HEPES, and 0.05 EGTA, pH adjusted
to 7.2 with NaOH and supplemented with freshly dissolved (every 1–2 h) 200 μg/ml
amphotericin-B in dimethyl sulfoxide. Bovine serum albumin was obtained from Thermo
Fisher Scientific (Fair Lawn, NJ). All other compounds were obtained from SigmaAldrich.
Data analysis and statistics. The TICCs were analyzed as open channel probability (NPo)
as previously described[78]. Data are summarized as means ± SEM for n (the number of
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DSM cells) isolated from N (the number of patients). Data were compared using a paired
Student's t-test. A P value <0.05 was considered statistically significant.
RESULTS
TRPM4 channels are colocalized with the IP3Rs in human DSM cells. In order for the
discrete Ca2+ release events from SR IP3Rs to regulate TRPM4 channel activity in human
DSM, the IP3Rs and TRPM4 channels must be located within close apposition. To
determine TRPM4 channel colocalization with IP3Rs, we conducted Duolink in situ PLA
on freshly-isolated human DSM cells. To elucidate TRPM4/IP3R colocalization, human
DSM cells were incubated with the anti-TRPM4 goat and anti-IP3R rabbit antibodies,
respectively. As shown in Fig. 6.1A-B, co-incubation of TRPM4 and IP3R antibodies
positively confirmed that TRPM4 channels and IP3Rs are located in close proximity (<40
nm) to the cell membrane as indicated by the bright red fluorescence. Fluorescent detection
was not observed when the anti-TRPM4 goat antibody was omitted (Fig. 6.1C). As a
negative control, we utilized a rabbit antibody specific for the voltage-gated KV7.5 channel
subtype, which is expressed in human DSM[90, 91], but not expected to interact with
TRPM4 channels. Incubation of human DSM cells with anti-TRPM4 and anti-KV7.5 rabbit
antibodies, respectively, resulted in no observable fluorescent signal (Fig. 1). Results were
confirmed in at least three human DSM cells.
IP3R pharmacological inhibition with xestospongin-C decreases transient inward
cation current activity in human DSM cells. In non-DSM cells, TRPM4 channels have
been shown to be regulated by Ca2+ release events originating from the SR IP3Rs[92].
Therefore, SR IP3R Ca2+ release activity may constitute a fundamentally important cellular
mechanism regulating TRPM4 channel activity in human DSM. To ascertain whether SR
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IP3Rs potentially regulate TRPM4 channel activity in human DSM, we examined the
physiological consequences of IP3R pharmacological inhibition on TRPM4 channelmediated TICCs. At the holding potential of -70 mV, where BK channel activity is
negligible[80], pharmacological inhibition of the IP3Rs with the selective inhibitor
xestospongin-C (1 µM) significantly reduced TICC activity (NPo) from 2.0±1.1 in control
conditions to 1.3±1.0 in the presence of 1 µM xestospongin-C (n=6, N=4; P<0.05; Fig.
6.2). These results support the concept that Ca2+ release events from SR IP3Rs are involved
in the regulation of TRPM4 channel-mediated TICCs in human DSM cells (Fig. 6.3).
DISCUSSION
This study sought to determine whether IP3Rs of the SR regulate TRPM4 channel
activity in human DSM function. This was achieved by elucidating IP 3R-TRPM4 channel
spatial and functional interactions in human DSM by utilizing in situ PLA and perforated
patch-clamp electrophysiology in combination with the IP3R inhibitor xestospongin-C. In
situ PLA confirmed co-localization between IP3Rs and TRPM4 channels in human DSM
isolated cells. Further, IP3R pharmacological inhibition with xestospongin-C led to the
attenuation of TICCs. This study established the novel finding that TRPM4 channels and
SR IP3Rs are physically and functionally coupled in the regulation of human DSM
excitability.
Several studies from our laboratory have revealed key roles for the TRPM4
channels in regulating the excitability and contractility of DSM in rodents[33, 79, 80].
More recently, we further explored the translational implications of our findings in rodents
by investigating the physiological roles for the TRPM4 channels in clinically-characterized
human DSM [78]. As summarized in a recent editorial article in the American Journal of
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Physiology Cell Physiology[86], our group revealed critical roles for the TRPM4 channels
in regulating DSM function. TRPM4 channel expression is abundant in human DSM and
species-related differences in the functional roles of the TRPM4 channels have been
reported between human and rodents[78]. This previous report by our group provided
compelling evidence at the cellular level in human DSM demonstrating the TRPM4
channel inhibitor 9-phenanthrol had a substantially greater inhibitory effect on DSM cell
excitability in human versus rodent DSM cells[78].
Utilizing the selective TRPM4 channel inhibitor 9-phenanthrol, we reported that
the pharmacological inhibition of the TRPM4 channels hyperpolarized the membrane
potential in human DSM cells and caused inhibition of spontaneous phasic,
pharmacologically-induced, and nerve-evoked contractions in human DSM isolated
strips[78]. Among the mechanisms underlying the inhibitory effects of 9-phenanthrol on
human DSM excitability and contractility includes the attenuation of TICCs[33, 78-80].
TICCs are caused by Na+ influx following Ca2+-dependent TRPM4 channel activation
which, under physiological conditions, functions to enhance DSM cell excitability[78, 93,
94].
As TRPM4 channels are activated by Ca2+, it was critically important to determine
the specific Ca2+-dependent molecular and cellular mechanisms involved in the regulation
of TRPM4 channel activity. Albeit well-known, there are two key sources for the elevation
of intracellular Ca2+ concentrations, including: 1) Ca2+ entry through L-type voltage-gated
Ca2+ channels at the cell membrane, or 2) Ca2+ release events through SR ryanodine
receptors or IP3Rs[57, 94]. In particular, emerging evidence from non-DSM cell types have
shown that members of the TRP channel family, including TRPM4, can be activated by
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intracellular Ca2+ released from SR IP3Rs. IP3R-mediated activation of adjacent TRPM4
channels, as has been reported in non-DSM cell types[87, 95], would lead to depolarization
of the cell membrane potential, activation of L-type voltage-gated Ca2+ channels, an
increase in global intracellular Ca2+ concentrations, and thus the activation of DSM
contractions. In fact, in cerebral artery myocytes, sustained TRPM4 channel activity was
shown to be dependent on Ca2+ released from the SR IP3Rs[96].
Given the critically important role for the TRPM4 channels in human DSM
excitability and contractility, we sought to examine whether IP3Rs and TRPM4 channels
functionally interact to regulate human DSM function. Our results demonstrated that
xestospongin-C, a selective IP3R inhibitor, significantly decreased TICC activity in human
DSM cells (Fig. 6.2). These results are consistent with IP3R-dependent regulation of
TRPM4 channels in human DSM by a similar mechanism as was suggested for cerebral
artery myocytes. Ca2+ released from the SR IP3Rs are localized and transient events as has
been demonstrated in murine colonic myocytes and rabbit portal vein myocytes[84, 97].
Hence, localized Ca2+ release events for the SR IP3Rs must be in close apposition to the
plasmalemmal TRPM4 channels in order for IP3R-TRPM4 channel functional coupling.
Thus, to ascertain the potential co-localization for the TRPM4 channels and IP3Rs, we
utilized the Duolink in situ PLA technique in combination with TRPM4 channel and IP3Rspecific antibodies. As illustrated by Fig. 6.1, in situ PLA experiments demonstrated the
co-localization of IP3Rs and TRPM4 channels in freshly-isolated human DSM cells within
the vicinity of the cell membrane. These results are in contrast to findings from arterial
myocytes, where IP3R co-localization was confirmed with TRPC3 channels, while no colocalization with either the TRPM4 or TRPC6 channels was found[98]. The existence of
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IP3R co-localization with TRPM4 channels in DSM, but not in arterial myocytes, may
suggest TRPM4 channel-IP3R spatial interactions follow, to an extent, a certain level of
tissue-specific expression.
While our current data provide strong evidence to support the spatial and functional
coupling of the IP3Rs and TRPM4 channels in human DSM (Fig. 6.3), we cannot exclude
potential involvement of alternative signaling pathways. IP3 and Ca2+ are the two central
modulators of SR IP3R activity[99]. Indeed, IP3R activity has been shown to be regulated
by IP3 generated downstream from the activation of Gq/11-coupled muscarinic receptor
pathways involving phospholipase C hydrolysis of phosphatidylinositol bisphosphate
(PIP2)[99]. Further, more recent studies have shown Ca2+-permeable TRPC6 channels are
spatially and functionally coupled with the SR IP3Rs in cerebral arterial myocytes[100].
Thus, TRPC6 activation of the IP3Rs lead to Ca2+ release events from the SR IP3Rs, which
then activate adjacent TRPM4 channels at the cell membrane[100]. Also, in the
vasculature, protein kinase C was shown to modulate vascular myogenic tone in a TRPM4
channel-dependent manner[101, 102]. Consistently, in a separate study on HEK cells
expressing cloned TRPM4 channels, the sensitivity for TRPM4 channels to Ca 2+dependent activation is enhanced by PKC phosphorylation[103]. Whether these potential
TRPM4 channel regulatory mechanisms exist in human DSM is yet to be explored.
However, as our data confirm IP3R-TRPM4 channel functional coupling, this work
represents a foundational study in the human urinary bladder and provides a solid platform
for subsequent mechanistic studies in human DSM (Fig. 6.3).
The key functional role of the TRPM4 channels in promoting DSM excitability has
provided an intriguing opportunity for potential therapeutic exploitation in the context of
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overactive bladder syndrome. Specifically, pharmacological modulators of the TRPM4
channels or mechanisms controlling their activity may represent a promising novel
approach for treatment of bladder dysfunction. Given the critical role of the TRPM4
channels in human DSM function and dysfunction, further efforts to ascertain TRPM4
channel regulatory mechanisms are critical for confirming and validating their potential
therapeutic utility. The current study has provided novel mechanistic insight into TRPM4
channel regulation by SR IP3Rs in human DSM. As current treatments for overactive
bladder lack efficacy, research efforts to identify novel therapeutic modalities are urgently
needed and examining TRPM4 channel physiologic roles and mechanisms of regulation is
of scientific and clinical relevance.
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Figure 6.1. TRPM4 channels are colocalized with the IP 3R of the sarcoplasmic
reticulum in freshly-isolated human DSM cells. A) Representative image of a human
DSM cell stained with the anti-TRPM4 goat polyclonal antibody and anti-IP3R rabbit
polyclonal antibody. As demonstrated in the merge panel in A, the orthogonal cross-section
image of the human DSM cell is shown in the rectangular box and represents the crosssectional plane as indicated by the white dashed line. B) Representative image of a human
DSM cells stained with only the anti-IP3R rabbit polyclonal antibody (negative control, no
signal detected). C) Representative image of a human DSM cell stained with the antiTRPM4 goat polyclonal antibody and the anti-KV7.5 rabbit polyclonal antibody (negative
control, no signal detected). As shown in A, positive co-localization of anti-TRPM4 and
anti-IP3R antibodies is exemplified by red fluorescent staining Results were confirmed in
at least three human DSM cells isolated from three different patients.
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Figure 6.2. IP3R inhibition with xestospongin-C decreased TICC activity in human
DSM cells. A) An original recording showing the inhibitory effect of xestospongin-C (1
µM) on TICCs in a human DSM single cell recorded at a holding potential of -70 mV. B)
Summary data illustrating the inhibitory effects of xestospongin-C (1 µM) on TICCs,
analyzed as single channel open probability (NPo) (n=6, N=4; *P<0.05).
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Figure 6.3. Illustration of the IP3R regulatory role of TRPM4 channels in human
DSM function. TRPM4 channels conduct monovalent cations and control human DSM
membrane potential. TRPM4 channels are controlled by IP3R-mediated Ca2+ release from
the sarcoplasmic reticulum as inhibition of the IP3Rs with xestospongin-C reduces TRPM4
channel activity. Pharmacological blockade of TRPM4 channels with 9-phenanthrol
hyperpolarizes the DSM cell membrane, inhibits the Ca2+ channels, reduces intracellular
Ca2+ levels and promotes DSM relaxation[78].
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CHAPTER 7
9

REGULATION OF GUINEA PIG DETRUSOR SMOOTH MUSCLE
EXCITABILITY BY 17Β-ESTRADIOL: THE ROLE OF THE LARGE
CONDUCTANCE VOLTAGE- AND CA2+-ACTIVATED K+ CHANNELS
ABSTRACT
Estrogen replacement therapies have been suggested to be beneficial in alleviating
symptoms of overactive bladder. However, the precise regulatory mechanisms of estrogen
in urinary bladder smooth muscle (UBSM) at the cellular level remain unknown. Large
conductance voltage- and Ca2+-activated K+ (BK) channels, which are key regulators of
UBSM function, are suggested to be non-genomic targets of estrogens. This study provides
an electrophysiological investigation into the role of UBSM BK channels as direct targets
for 17β-estradiol, the principle estrogen in human circulation. Single BK channel
recordings on inside-out excised membrane patches and perforated whole cell patch-clamp
were applied in combination with the BK channel selective inhibitor paxilline to elucidate
the mechanism of regulation of BK channel activity by 17β-estradiol in freshly-isolated
guinea pig UBSM cells. 17β-Estradiol (100 nM) significantly increased the amplitude of
depolarization-induced whole cell steady-state BK currents and the frequency of
spontaneous transient BK currents in freshly-isolated UBSM cells. The increase in whole
cell BK currents by 17β-estradiol was eliminated upon blocking BK channels with
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paxilline. 17β-Estradiol (100 nM) significantly increased (~3-fold) the single BK channel
open probability, indicating direct 17β-estradiol-BK channel interactions. 17β-Estradiol
(100 nM) caused a significant hyperpolarization of the membrane potential of UBSM cells,
and this hyperpolarization was reversed by blocking the BK channels with paxilline. 17βEstradiol (100 nM) had no effects on L-type voltage-gated Ca2+ channel currents recorded
under perforated patch-clamp conditions. This study reveals a new regulatory mechanism
in the urinary bladder whereby BK channels are directly activated by 17β-estradiol to
reduce UBSM cell excitability.
Abbreviations: BK channels, large conductance voltage- and Ca2+-activated K+ channels;
CaV channels, L-type voltage-gated Ca2+ channels; DMSO, dimethyl sulfoxide; UBSM,
urinary bladder smooth muscle; EGTA, ethylene glycol-bis(2-aminoethylether)N,N,N',N'-tetraacetic acid; HEPES, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid;
Po, single channel open probability; NPo, single channel total open probability of each
excised patch; OAB, overactive bladder; RyRs, ryanodine receptors; SR, sarcoplasmic
reticulum; TBKCs, transient BK currents
INTRODUCTION
The functions of the urinary bladder, which are to store and periodically release
urine, are facilitated by the contraction and relaxation of urinary bladder smooth muscle
(UBSM). Overactive bladder (OAB), a highly prevalent chronic health condition in the
United States, is often associated with increased UBSM contractility. The primary
treatment for OAB involves antimuscarinic agents, which have limited efficacy and
tolerability [12]. Many forms of OAB have been linked directly to UBSM dysfunction [12,
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105]. Therefore, novel therapeutic modalities for OAB, targeting UBSM directly, are
urgently needed.
Sharing a common embryonic origin, the genital and lower urinary tract systems
are both regulated by sex hormones, including estrogens [106, 107]. Systemic and vaginal
estrogen therapies have been considered beneficial in alleviating symptoms of OAB in
postmenopausal women [106, 107]. Epidemiological studies have also linked postmenopausal estrogen deficiencies with the increased risk for OAB [106]. Despite these
observations, conflicting evidence in the literature exists concerning the role of estrogen as
a treatment for OAB [106]. Some studies suggest beneficial effects of estrogen replacement
therapies for controlling symptoms of OAB, while other studies report the opposite [106108]. Thus, there remains the need for an improved understanding of the mechanisms by
which estrogens regulate UBSM function [108].
The predominant estrogen in human circulation is 17β-estradiol, a potent hormone
known to regulate urinary bladder function [106, 107, 109, 110]. 17β-Estradiol-induced
UBSM relaxation has long been established in vitro [111-113] and in vivo [114]. The
cellular mechanisms of these functional effects of 17β-estradiol in UBSM are not well
understood, but several mechanisms have been suggested, including L-type voltage-gated
Ca2+ (CaV) channel inhibition [105, 112] and K+ channel activation [115]. Among the K+
channel targets of 17β-estradiol are the large conductance voltage- and Ca2+-activated K+
(BK) channels [116-119]. A previous study in guinea pigs [115] suggested the possible
involvement of the BK channels in 17β-estradiol-induced UBSM relaxation as the relaxant
effects of 17β-estradiol were concentration-dependently blocked by the specific BK
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channel inhibitor iberiotoxin. However, the role of the BK channels as targets for 17βestradiol has never been investigated at the cellular level in UBSM.
BK channels are among the most physiologically-relevant K+ channels regulating
UBSM excitability and contractility [4, 11]. As both a Ca2+ and voltage sensor, BK
channels work to oppose UBSM excitability by promoting cell membrane
hyperpolarization, which in turn precludes Ca2+ influx through L-type CaV channels to
promote UBSM relaxation [4, 11]. In UBSM, BK channels are activated by either Ca2+
influx through L-type CaV channels or by Ca2+ released from the sarcoplasmic reticulum
(SR) ryanodine receptors (RyRs), known as “Ca2+ sparks” [11]. BK channel activation by
Ca2+ sparks triggers transient BK currents (TBKCs), also known as spontaneous transient
outward currents (STOCs) [11], which regulate UBSM excitability. Given the key role of
the BK channels in UBSM function [4, 11], their potential regulation by 17β-estradiol
represents a critically important mechanism in UBSM cell physiology. Indeed, an earlier
study proposed a potential role for the BK channels in 17β-estradiol-mediated UBSM
relaxation [115]. However, in UBSM, the existence of a 17β-estradiol-BK channel
functional interaction has not been investigated at the cellular level. Therefore, this study
aimed to elucidate the functional role of the BK channels as non-genomic targets of 17βestradiol in guinea pig UBSM cell excitability. We employed multiple electrophysiological
protocols including single BK channel recordings on inside-out excised membrane patches
and the amphotericin-B perforated whole cell patch-clamp technique in combination with
the selective BK channel inhibitor paxilline.
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MATERIALS AND METHODS
UBSM tissue acquisition and single cell isolation. All experimental procedures were
conducted in accordance with the animal use protocol #2186 reviewed and approved by
the Institutional Animal Care and Use Committee (IACUC) of the University of South
Carolina. Only male animals were used in this study to avoid changes in the estrogen levels
that occur during the menstrual cycle of the females. Forty-six adult male Hartley-Albino
guinea pigs (Charles River Laboratories, Raleigh, NC) of average weight 740±177 g were
euthanized by CO2 inhalation using a SMARTBOX™ automated CO2 delivery system
(Euthanex Corp, Palmer, PA) followed by thoracotomy. Subsequently, the urinary bladder
was removed after a transverse incision superior to the bladder neck. Dissection of UBSM
tissues was performed as previously described [120]. UBSM single cells were isolated from
UBSM tissues by enzymatic digestion using a combination of collagenase and papain as
previously described [120]. Freshly-isolated UBSM cells were used for patch-clamp
experiments within 12 h of isolation.
Patch-clamp electrophysiology. UBSM cell suspension (0.3-0.5 ml) was placed in a
glass-bottom chamber to settle for at least 20-30 min. We applied the amphotericin-B
perforated whole cell patch-clamp technique as previously described [120] to record
voltage-step depolarization-induced whole cell BK currents, TBKCs, L-type CaV currents,
and the resting membrane potential of freshly-isolated guinea pig UBSM cells. To
determine the effects of 17β-estradiol on whole cell steady-state BK currents, UBSM cells
were voltage-clamped at a holding potential of -70 mV. Subsequently, voltage-step
depolarizations were applied from -40 to +80 mV at 20 mV intervals for 200 ms.
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Membrane potential recordings were performed in current-clamp mode (I=0) of the patchclamp technique. The effects of 17β-estradiol on peak L-type CaV channel
currents were recorded at 0 mV in voltage-clamp mode of the amphotericin-B perforated
patch-clamp technique in the presence of paxilline (1 µM). Single BK channel recordings
were performed on inside-out excised membrane patches as previously described [120].
Single BK channel currents were measured at -60 mV with bath and pipette solutions
containing symmetrical 140 mM KCl and ~300 nM free [Ca2+] (see §Solutions and
drugs). These experiments were conducted using pCLAMP version 10.2 software
(Molecular Devices, Sunnyvale, CA) with an Axopatch 200B amplifier (Digidata 1322A).
Currents were filtered using an eight-pole Bessel filter (model 900CT/9L8L, Frequency
Devices, Ottawa, IL). Borosilicate glass patch-clamp pipettes (Sutter Instruments, Novato,
CA) were pulled using a Narishige glass micropipette puller (model PP-830, Narishige
Group, Tokyo, Japan) and polished with a Microforge (model MF-830, Narishige Group).
The final pipette resistance was 4-6 MΩ for whole cell patch-clamp and 6-15 MΩ for single
BK channel recordings. All patch-clamp experiments were conducted at room temperature
(22-23°C).
Solutions and drugs. Ca2+-free dissection solution contained (in mM): 80 monosodium
glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 N-2-hydroxyethylpiperazine-N'-2ethanesulphonic acid (HEPES); 2 MgCl2; NaOH was administered to attain pH 7.3. The
extracellular solution for whole cell patch-clamp experiments had (in mM): 134 NaCl, 6
KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES, pH adjusted to 7.4 with NaOH. The
patch-pipette solution contained (in mM): 110 potassium aspartate; 30 KCl; 10 NaCl; 1
MgCl2; 10 HEPES; 0.05 ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
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(EGTA); NaOH was used to adjust the pH to 7.2. Symmetrical K + solution used for single
BK channel recordings contained (in mM): 140 KCl, 1.08 MgCl2, 5 EGTA, and 3.16 CaCl2,
adjusted to pH 7.2 with NaOH. Stock amphotericin-B solution was freshly prepared daily
in dimethyl sulfoxide (DMSO) and was added to the
pipette solution (200-300 μg/ml) prior to the experiment. 17β-Estradiol and paxilline were
purchased from Sigma-Aldrich (St. Louis, MO) and were dissolved in DMSO. The final
concentration of DMSO in the bath solution did not exceed 0.01%.
Data analysis and statistics. Single BK channel openings were analyzed over 5-10 min
intervals before and after the addition of 17β-estradiol (100 nM). The values for single BK
channel open probability [107] of each excised patch (NPo) were calculated using Clampfit
10.2 software as previously described [120]. Single BK channel Po for each patch was
calculated as NPo where N refers to the number of channels in the patch. The effects of
17β-estradiol on whole cell steady-state BK currents and the cell membrane potential were
analyzed using Clampfit 10.2 software. The effects of 17β-estradiol on voltage-step
depolarization-induced whole cell BK currents were analyzed by taking the average value
of the last 50 ms of each pulse before and after the application of 17β-estradiol (100 nM).
The effects of 17β-estradiol on the amplitude and frequency of TBKCs were analyzed using
Minianalysis software (Synaptosoft, Decatur, GA). The threshold of TBKCs was set at 9
pA, which is equal to three times the single BK channel amplitude at -20 mV. Data are
presented as the means ± SEM. In the summarized data, “n” indicates the number of UBSM
cells used and “N” represents the total number of guinea pigs. CorelDraw Graphics Suite
X3 software (Corel Co., Mountain View, CA) and GraphPad Prism 4.03 software
(GraphPad Software, Inc., La Jolla, CA) were used for statistical analysis and data
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illustration. Paired Student’s t-test was used for statistical analysis. P values <0.05 were
considered statistically significant.
RESULTS
17β-Estradiol enhanced whole cell depolarization-induced steady-state K+ currents in
freshly-isolated UBSM cells. The average whole cell capacitance of all cells used in the
present study was 29.8±2.2 pF (n=64, N=46). 17β-Estradiol (100 nM) caused a significant
increase in whole cell steady-state K+ currents (n=11, N=10; P<0.05, Fig. 1A-B). As
illustrated in Fig. 1A-B, the density of whole cell steady-state K+ currents at +80 mV were
30.1±14.6 pA/pF for the controls and 35.8±16.0 pA/pF in the presence of 17β-estradiol.
To determine whether these stimulatory effects were mediated by the BK channels, we
examined the effects of 17β-estradiol in the presence of the BK channel inhibitor paxilline
(1 µM). As shown in Fig. 1C-D, when BK channels were blocked with 1 µM paxilline,
17β-estradiol had no significant effects on the residual whole cell steady-state K+ currents.
The density of whole cell steady-state K+ currents at +80 mV was 13.5±2.3 pA/pF for the
controls (paxilline only) and after the application of 17β-estradiol in the continued presence
of paxilline was 13.4±2.4 pA/pF (n=14, N=12; P>0.05; Fig. 1C-D). These results indicate
that in UBSM cells, the increase in whole cell steady-state K+ currents by 17β-estradiol is
mediated by the BK channels
17β-Estradiol increased the frequency of TBKCs in freshly-isolated UBSM cells.
TBKCs have a key role in regulating UBSM cell excitability [4, 11]. We sought to elucidate
the regulation of TBKC activity by 17β-estradiol in UBSM cells. TBKCs were recorded at
a holding potential of -20 mV. As illustrated in Fig. 2, 17β-estradiol (100 nM) significantly
increased the frequency of TBKCs from 0.48±0.15 Hz (control) to 0.59±0.18 Hz (n=9,
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N=9; P<0.05), without effecting TBKC amplitude (n=9, N=9; P>0.05). Collectively, these
data indicate that 17β-estradiol regulates TBKC activity in UBSM cells.
17β-Estradiol increased single BK channel Po in UBSM cell excised membrane
patches. To elucidate if 17β-estradiol has a direct effect on the BK channels, we conducted
single BK channel recordings on inside-out excised membrane patches. 17β-Estradiol (100
nM) increased the mean BK channel NPo from the control value of 0.05±0.03 to 0.20±0.07
(n=13, N=11; P<0.05). Further, as illustrated in Fig. 3, single BK channel opening events
were completely abolished by 1 µM paxilline in all excised membrane patches. These data
provide strong support that 17β-estradiol directly and rapidly activates BK channels in
UBSM cells.
17β-Estradiol hyperpolarized the resting membrane potential of UBSM cells. Next,
we aimed to elucidate the BK channel-dependent regulation of the UBSM cell membrane
potential by 17β-estradiol in UBSM cells. 17β-Estradiol (100 nM) significantly
hyperpolarized the UBSM cell membrane potential to -25.8±2.3 mV from the control value
of -22.1±2.4 mV (n=12, N=11; P<0.05; Fig. 4A-B). The BK channel inhibitor paxilline (1
µM) reversed the hyperpolarizing effects of 17β-estradiol on the UBSM cell membrane
potential to -22.2±1.9 mV (n=12, N=11; P<0.05; Fig. 4A-B). As shown in Fig. 4C-D, 17βestradiol had no effects on the UBSM cell membrane potential when administered in the
presence of paxilline (1 µM), with the membrane potential of -19.3±6.7 mV in comparison
to the control (paxilline only) value of -20.0±7.0 mV (n=7, N=7; P>0.05). These data
support the concept that 17β-estradiol regulates the UBSM cell membrane potential
through a mechanism involving the modulation of BK channel activity.
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17β-Estradiol did not inhibit L-type CaV currents in freshly-isolated UBSM cells. In
guinea pig UBSM cells, the inhibition of L-type CaV currents by 17β-estradiol has been
reported at micromolar concentrations using the conventional patch-clamp technique
[112], which does not maintain the native physiological environment of UBSM cells. Thus,
we sought to determine whether nanomolar concentrations of 17β-estradiol (100 nM)
modulates L-type CaV channel activity in UBSM cells in the presence of the BK channel
inhibitor paxilline (1 µM) using the perforated patch-clamp technique. As exemplified by
Fig. 5, 17β-estradiol (100 nM) had no effect on L-type CaV channel currents. At 0 mV, the
average inward current density under control conditions was -1.4±0.3 pA/pF and after the
addition of 100 nM 17β-estradiol was -1.6±0.4 pA/pF (n=5, N=5; P>0.05; Fig. 5). These
results support the novel concept that under physiological conditions of the perforated
patch-clamp, nanomolar concentrations of 17β-estradiol do not directly affect L-type CaV
channel activity.
DISCUSSION
The current study provided the first electrophysiological evidence establishing the
novel regulatory mechanism by which the BK channels are direct targets for 17β-estradiol
at nanomolar concentrations in guinea pig UBSM cells. Our results demonstrate that 17βestradiol: 1) rapidly increases the amplitude of whole cell steady-state BK currents; 2)
rapidly increases the frequency of TBKCs; 3) rapidly increases single BK channel NPo;
and 4) hyperpolarizes the UBSM cell membrane potential; and 5) does not directly inhibit
L-type CaV channel currents at nanomolar concentrations. 17β-Estradiol is most widely
known for its long-term genomic mechanisms involving gene expression and the
promotion of female sexual and reproductive health.
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Figure 7.1 17β-Estradiol increases depolarization-induced whole cell steady-state BK
currents in freshly-isolated UBSM cells. A) Representative traces from a voltage-clamp
experiment illustrating that 17β-estradiol (100 nM) increases whole cell steady-state BK
currents in an isolated UBSM cell. B) The current-voltage relationship curves illustrate the
17β-estradiol (100 nM)-mediated increase of whole cell steady-state BK currents in
isolated UBSM cells (n=11, N=10; *P<0.05). C) Representative traces from a voltageclamp experiment illustrating the lack of effects of 17β-estradiol (100 nM) on whole cell
steady-state BK currents in the presence of the BK channel inhibitor paxilline (1 µM). D)
The current-voltage relationship curves illustrate that 17β-estradiol (100 nM) had no
significant effects on whole cell steady-state BK currents in the presence of 1 µM paxilline
(n=14, N=12; P>0.05).
However, emerging evidence in UBSM and other cell types suggests the existence of
several non-genomic mechanisms of 17β-estradiol, which may acutely influence cell
excitability and contractility.
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Figure 7.2 17β-Estradiol increases the frequency of TBKCs in freshly-isolated UBSM
cells. A) An original representative recording illustrating the stimulatory effects of 17βestradiol (100 nM) on TBKC activity in an isolated UBSM cell. B) Summarized data
illustrating the increase in TBKC frequency by 17β-estradiol (100 nM) in UBSM cells
(n=9, N=9; *P<0.05).
These non-genomic mechanisms include: inhibition of L-type CaV channels [112, 121,
122], endothelial-dependent release of nitric oxide [123], activation of protein kinases
[124], and activation of the BK channels [116, 125]. Involvement of the BK channels in
the mechanism of 17β-estradiol-induced response is supported by studies from non-UBSM
cell types and recombinant systems expressing BK channels, which indicate the activation
of BK channels by 17β-estradiol is dependent on their regulatory β1-subunit [108, 116119]. The role of the regulatory β1-subunit was also supported by studies from freshlyisolated murine colonic myocytes, where the increase in BK channel Po by 17β-estradiol
was not observed in excised membrane patches from β1-subunit knockout (β1-/-) mice
[126].
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Figure 7.3. 17β-Estradiol increases single BK channel Po in excised patches from
freshly-isolated UBSM cells. A) An original representative recording of BK channel
currents recorded in the inside-out configuration of the patch-clamp technique before and
after the addition of 100 nM 17β-estradiol in an excised patch from an isolated UBSM cell.
Single channel activity was completely abolished by 1 µM paxilline. “O” indicates open
channel state and “C” indicates closed channel state. B) Summarized data for the effects
of 17β-estradiol (100 nM) on the BK channel NPo (n=13, N=11; *P<0.05). Single BK
channel recordings were performed at a holding potential of -60 mV.
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Figure 7.4. 17β-Estradiol hyperpolarized the membrane potential of freshly-isolated
UBSM cells. A) A representative trace of a membrane potential recording in current-clamp
mode (I=0) demonstrating the hyperpolarizing effects of 17β-estradiol (100 nM) in an
isolated UBSM cell. The hyperpolarizing effect of 17β-estradiol (100 nM) was reversed by
1 µM paxilline. B) Summarized data illustrating the hyperpolarizing effects of 17βestradiol on the UBSM cell membrane potential and that 1 µM paxilline reverses the 17βestradiol-induced hyperpolarization (n=12, N=11; *P<0.05). C) A representative trace of
a membrane potential recording in current-clamp mode demonstrating that when the BK
channels are blocked with 1 µM paxilline, 17β-estradiol (100 nM) did not cause membrane
hyperpolarization in an isolated UBSM cell. D) Summarized data illustrating that 17βestradiol had no effect on the UBSM cell membrane potential in the presence of 1 µM
paxilline (n=7, N=7; P>0.05).
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Figure 7.5. 17β-Estradiol does not inhibit L-type CaV channel activity in freshlyisolated UBSM cells. A) A representative recording of the peak L-type CaV channel
currents recorded at 0 mV in a freshly-isolated UBSM cell in the absence (control) or
presence of 17β-estradiol (100 nM). B) Summary data of the current density of L-type CaV
channel currents in the absence (control) or presence of 100 nM 17β-estradiol (n=5, N=5;
P>0.05).
In UBSM, in vitro functional studies have demonstrated the inhibition of rodent
and pig UBSM contractility by 17β-estradiol [111, 113, 115]. These observations
correspond to reports in rat UBSM, where 17β-estradiol decreased the amplitude and
frequency of spontaneous Ca2+ flashes [113]. A previous study showed that 17β-estradiolinduced inhibition of UBSM contractility was still achieved in the presence of the estrogen
receptor antagonist ICI-182,780 [113]. This finding supports a non-genomic
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mechanism for 17β-estradiol in controlling UBSM contractility that is independent of
estrogen receptor activation. In guinea pig UBSM, it has been suggested that 17β-estradiol
acts as both an L-type CaV channel inhibitor and K+ channel activator [115]. It has been
shown that micromolar concentrations of 17β-estradiol inhibit L-type Ca2+ currents in
guinea pig UBSM cells [112], while a separate study showed the relaxant effects of 17βestradiol on guinea pig UBSM contractility were blocked in a concentration-dependent
manner by the selective BK channel inhibitor iberiotoxin [115]. As BK and L-type CaV
channels are functionally coupled [4, 11], it was important to elucidate these pathways at
the cellular level in UBSM using nanomolar concentrations of 17β-estradiol under
physiological experimental conditions.
Our results show that 17β-estradiol increased the amplitude of whole cell steadystate K+ currents (Fig. 1) consistent with reports in non-UBSM cell types [117, 126]. The
rapid effects of 17β-estradiol on whole cell K+ currents were blocked by the BK channel
inhibitor paxilline, suggesting a BK channel-dependent mechanism.
Directly confirming the 17β-estradiol-BK channel functional interactions, we
found that 17β-estradiol (100 nM) significantly increased the single BK channel NPo of
inside-out excised membrane patches of UBSM cells (Fig. 3). These results are in support
of earlier electrophysiological reports in non-UBSM cell types showing activation of the
BK channels by 17β-estradiol [116-119, 127]. Our single BK channel recordings were
performed using symmetrical K+ solutions with fixed Ca2+ concentration and in the absence
of signaling pathways that may alter BK channel Po. The rapid effects of 17β-estradiol on
the UBSM BK channels further indicate direct non-genomic mechanisms. Thus, our data
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provide clear-cut evidence that 17β-estradiol directly activates BK channels in UBSM
cells.
In UBSM cells, Ca2+ sparks released from the SR RyRs activate TBKCs, which
fundamentally regulate UBSM cell excitability [4, 11]. Activation of TBKCs
hyperpolarizes the UBSM cell membrane potential and decreases Ca2+ influx through Ltype CaV channels [4, 11]. 17β-Estradiol (100 nM) caused a significant increase in the
frequency of TBKCs (Fig. 2). While we cannot completely exclude the possibility that
17β-estradiol may regulate BK channel activity indirectly through modulating the SR Ca2+
sparks, the current data (Fig. 3) are in support of a non-genomic mechanism involving a
direct 17β-estradiol-BK channel interaction. Thus, the increase in TBKC frequency could
be explained by an increase in BK channel NPo by 17β-estradiol, which can thus increase
the number of single BK channel opening events at -20 mV (Fig. 2). Therefore, 17βestradiol increased the number of small BK channel opening events reaching the TBKC
threshold of 9 pA, (see Materials and Methods) as a result of direct modulation of BK
channel NPo while having no statistically significant effect on TBKC amplitude.
The negative feedback mechanism by which BK channels limit UBSM excitability
originates from its ability to control the cell membrane potential [11]. 17β-Estradiol (100
nM) caused a BK channel-dependent cell membrane hyperpolarization in UBSM cells
(Fig. 4). 17β-Estradiol-mediated hyperpolarization in UBSM cells is consistent with the
stimulatory effects of 17β-estradiol on TBKCs and whole cell steady-state BK currents.
Our study is the first to reveal a direct functional role for the BK channels in
mediating the effects of 17β-estradiol in UBSM at the cellular level. Importantly, the
effects of 17β-estradiol on BK channel activity in the current study were achieved using a
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nanomolar concentration, well below the micromolar concentrations previously used in
UBSM functional
studies [111-113, 115]. In particular, it was previously reported using the conventional
patch-clamp technique that 17β-estradiol, at much higher non-physiological micromolar
concentrations (1 µM), inhibited peak Ca2+ currents by 50% in guinea pig UBSM cells
[112]. However, 17β-estradiol never reaches micromolar concentrations in the blood
plasma even under pathophysiological conditions. We demonstrated here for the first time
using the perforated whole cell patch-clamp technique, that 17β-estradiol (100 nM) had no
direct effects on L-type CaV channel activity in freshly-isolated guinea pig UBSM cells
(Fig. 5). These data suggest that 17β-estradiol directly activates the BK channels at
nanomolar concentrations, which are insufficient to affect L-type CaV channel activity.
Unlike our study, previous studies that showed L-type CaV channel inhibition by 17βestradiol in guinea pig UBSM cells have used physiologically-irrelevant high micromolar
concentrations [112]. Thus, our study reveals the novel findings that L-type CaV channel
inhibition by 17β-estradiol is not involved in UBSM relaxation under normal physiological
conditions.
The current study provides strong evidence supporting a role for the BK channels
as low-affinity non-genomic targets for 17β-estradiol in UBSM. Our study does not
exclude the possibility that 17β-estradiol may exert genomic effects on the BK channels
directly through estrogen receptor stimulation. However, the rapid increase in single BK
channel NPo by 17β-estradiol (Fig. 3) clearly indicates that the BK channels are direct nongenomic targets for 17β-estradiol. As the role of estrogens in UBSM physiology and
pathophysiology is not fully understood, the current study provides a foundational basis
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for future studies in human UBSM. Indeed, decreased estrogen levels have been associated
with the increased occurrence of urinary urgency and frequency in post-menopausal
women [106-108, 128]. Thus, the activation of the BK channels by 17β-estradiol, which in
turn hyperpolarizes the membrane potential to cause UBSM relaxation, may underlie some
of the observed benefits of estrogen replacement therapies in alleviating symptoms of OAB
[108].In conclusion, we reveal a new paradigm in UBSM cell physiology, indicating a
direct role for the BK channels in mediating the inhibitory effects of 17β-estradiol on
UBSM cell excitability.
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